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Abstract
Acute myelogenous leukemia (AML) and its precursors are the result of the
dysregulation of hematopoiesis. Hematopoiesis proceeds in a stepwise manner,
beginning with hematopoietic stem cells, continuing to develop into various stages of
progenitor cells, and finally becoming fully functional blood cells. As this process goes
awry, immature, functionless cells of the myeloid lineage proliferate out of control.
Discerning how myeloid progenitor frequency is regulated allows for a better
understanding of how the process may lose control. Hematopoiesis has been shown to
depend on genetic and environmental factors. In this work, I have added to this
knowledge base by providing novel information about genetic and environmental
components for the regulation of blood cell development. By performing colony forming
cell (CFC) assays to determine myeloid progenitor cell frequency in 27 strains of mice,
and using bioinformatics capabilities in the form on SNP-based in silico mapping, I have
found patterns among genes located in chromosomal loci of interest for regulating this
phenotype. These patterns suggest that lipid metabolism, insulin sensitivity, and bone
properties are key regulators of myelopoiesis. Additionally, I have found that
polyunsaturated fatty acid (FA) content in the diet is a key environmental regulator. Mice
fed diets rich in omega-3 FAs have significantly lower middle and late stage progenitor
cell frequency and increased common myeloid progenitor frequency over those fed more
similarly to the Western diet. Collectively these data suggest that the content of diet, how
it is metabolized by the body, and how this affects the bone, regulates the frequency of
myeloid progenitor cells. Further research into these processes may provide novel
biomarkers for disease progression and improved therapeutic options for AML.
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Chapter 1: Introduction
Hematopoiesis
Hematopoiesis refers to the process by which blood cells develop. During
hematopoiesis, a continuum of differentiation exists, such that long term hematopoietic
stem cells (LT-HSCs) progressively differentiate to produce terminally differentiated
cells of the blood (Fig1.1). LT-HSCs, which have infinite self-renewal capabilities,
divide asymmetrically producing short term hematopoietic stem cells (ST-HSCs), which
have limited self-renewal capacity. ST-HSCs give rise to highly proliferative multipotent
progenitor cells (MPPs), which differentiate further, giving rise to the common
progenitors of the lymphoid and myeloid lineages [1-3].
During myelopoiesis, the common myeloid progenitor gives rise to middle stage
progenitors including granulocyte monocyte progenitors (GMPs) and erythrocyte
megakaryocyte progenitors (EMPs). These have more limited differentiation potential.
The common myeloid progenitor also gives rise to the late stage or committed
progenitors for the formation of basophils and eosinophils. The GMPs can then
differentiate further to committed progenitors for granulocytes and monocytes, whereas
EMPs can differentiate further to committed progenitors for erythrocytes and
megakaryocytes. These progenitors make up the myeloid progenitor cell compartment
(Fig.1.1) [4].
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Figure 1.1: Progenitor cells represent a continuum of differentiated cell types
derived from the HSC. Successive stages of differentiation of the lymphoid lineage
eventually lead to the formation of mature cells, including B and T cells and natural killer
cells. Successive stages of differentiation of the myeloid lineage eventually lead to
formation of mature neutrophils, basophils, macrophages, megakaryocytes and
erythrocytes. The cells within the red background make up the myeloid progenitor cell
compartment. Abbreviations: hematopoietic stem cell (HSC), common myeloid
progenitor cell (CMP), common lymphoid progenitor cell (CLP), erythroid and
megakaryocyte progenitor cell (EMP), and granulocyte and monocyte progenitor cell
(GMP). The committed progenitor cells are abbreviated as follows: neutrophil (MP-N),
monocyte (MP-M), eosinophil (MP-Es), basophil (MP-B), erythrocyte (MP-E), and
megakaryocyte (MP-Meg).
2

This process of blood cell development occurs first within the yolk sac of
embryos. As development continues, it takes place in the liver, spleen, and lymph nodes.
As bone marrow develops, it becomes the location of blood development. Maturation and
activation of lymphoid cells occur in the thymus, spleen, and lymph nodes [5]. Bone
marrow is found within the interior of bones and exists in two forms. Red marrow
consists mainly of hematopoietic tissue, and yellow marrow consists mostly of fat cells.
As aging occurs, more and more red marrow is converted to yellow marrow, but in cases
of severe blood loss, the body can convert yellow marrow to red marrow to increase
blood production. The stroma of the bone marrow consists mostly of yellow marrow.
Additionally it contains fibroblasts, macrophages, adipocytes, osteoblasts, osteoclasts,
endothelial cells, and mesenchymal stem cells. The stroma of bone marrow forms the
hematopoietic microenvironment, containing components that can influence the process
of hematopoiesis [6.7].
Some hematopoietic cells in the bone marrow exist adjacent to endosteal bone
surface. The endosteum is a thin layer of connective tissue that lines the surface of the
bony tissue that forms the medullary or bone marrow cavity of long bones. Endosteum is
lined primarily by osteoblasts, which are responsible for bone formation and have been
shown to produce a variety of cytokines including granulocyte colony-stimulating factor
(G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), and interleukin6 (IL-6) [8]. Due to their role in producing these cytokines that are important for
hematopoietic cell differentiation, it has been hypothesized that osteoblasts are key
regulators of hematopoiesis [9]. Osteoclasts, on the other hand, are responsible for bone
resorption. High levels of calcium, magnesium, phosphate and products of collagen are
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released as osteoclasts break down mineralized bone. Findings from the Kollet laboratory
suggest that, in stress-induced situations, osteoclasts degrade endosteal components and
promote the mobilization of hematopoietic progenitor cells [10]. The opposing effects of
bone-forming osteoblasts and bone-resorbing osteoclasts control the content of bone
inner wall and the endosteum region and, therefore, the environment surrounding the
location of hematopoiesis.

Acute myelogenous leukemia and its precursors
Hematopoiesis is known to be influenced by genetic and environmental factors. In
situations in which this process becomes dysfunctional, hematopoietic malignancies may
develop. Myeloproliferative diseases of the bone marrow are conditions in which excess
cells of the myeloid lineage are produced. These diseases may develop into
myelodysplastic syndromes or acute myelogenous leukemia (AML). Myelodysplastic
syndromes are dysplasias or ineffective production of the myeloid cells in the bone
marrow. These syndromes have risk for transformation into AML. In AML, precursor
cells of the myeloid lineage undergo impaired differentiation and clonal expansion. The
clinical diagnosis for AML occurs when the percentage of these immature and therefore
functionless cells rises beyond a particular level in the bone marrow (20-30%) [11]. In
AML, the overproduction of these cells prevents the production of normal functioning
red and white blood cells. Without the proper amount of functioning red and white blood
cells, patients become anemic and slow to fight off infections. Understanding why
immature myeloid cells proliferate rapidly and cease to differentiate is essential in
understanding why these hematopoietic malignancies can occur. My research is designed
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to improve this understanding by identifying genetic and environmental factors that
control the frequency of myeloid progenitor cells in the bone marrow.

Genetics of hematopoiesis
A number of genes are involved in controlling the process of hematopoiesis. Hox,
Stat, and Gata genes in addition to Pu.1, C-myb, Runx1, Slc, IL-3R, and others have
been shown regulate this process [12-21]. Some of these are also observed in
chromosomal translocations in leukemias. Hox genes control differentiation,
proliferation, and cell fate during hematopoiesis [12-14]. Stat-3 and Stat-5 allow for
survival and differentiation of myeloid hematopoietic cells [15]. Gata-1 and Pu.1 control
hematopoietic cell fate by antagonizing one another through direct physical interaction
[16]. Gata-1 promotes erythromegakaryocytic differentiation while Pu.1 regulates
myelolymphoid differentiation. Gata-1 directly binds to and suppresses Pu.1. Conditional
knock-out studies have indicated that c-Myb is required for self-renewal of hematopoietic
stem cells [17]. Runx1 is a master regulator of hematopoiesis [18]. Scl controls
transcriptional programs during embryonic hematopoiesis and is vital to megakaryocyte
and erythrocyte development [19-20]. Deletions in IL-3Rare known to cause decreased
hematopoietic progenitor cell frequency [21]. The chromosomal region containing this
gene served as a control for our studies as it has been shown that several of the mouse
strains we included in our studies contain the 5bp deletion in IL-3R that causes low
myeloid progenitor cell frequency.
Chromosomal translocations, deletions, and genetic mutations are common in
hematopoietic malignancies. Philadelphia chromosome is a reciprocal translocation
5

between chromosomes 9 and 22 resulting in an oncogenic fusion protein, BCR-ABL.
This translocation occurs in the myeloproliferative disease of chronic myelogenous
leukemia (CML) [22]. Other myeloproliferative diseases are often associated with
mutations in JAK2 [23-25]. One type of myelodysplastic syndrome is also associated
with JAK2 mutations [26]. A particular myelodysplastic syndrome called 5q- syndrome
is caused by deletions in the long arm of chromosome 5. These deletions cause anemia
and megakaryocytic dysplasia. AML is associated with characteristic chromosomal
abnormalities such as translocations between chromosomes 8 and 21
(RUNX1/RUNX1T1), translocations between chromosomes 1 and 17 (RARA/PML), or
inversions in chromosome 16 (CBFB/MYH11) among others. These chromosomal
aberrations are key indicators of disease prognosis. There are also several gene mutations
that have been shown to influence the outcome of the disease. These genes include Flt3,
Npm1, and Kit. Flt3 internal tandem duplications are associated with poorer prognosis in
AML. Npm1 gene mutations are the most frequent genetic alteration found in AML. Kit
is a cytokine receptor expressed on hematopoietic stem cells and involved in promoting
stem cell maintenance. Survival rates and relapse risk for AML rely heavily on
cytogenetic constitutions and the presence of mutations in the genes mentioned above
[27-30].
Table 1.1: Survival and relapse rate associations with chromosomal abnormalities
Risk Category
Good
Intermediate
Poor

Abnormality
t(8;21), t(15;17), inv(16)
Normal, +8, +21, +22, del(7q), del(9q),
Abnormal 11q23, all other structural or
numerical changes
-5, -7, del(5q), Abnormal 3q, Complex
cytogenetics
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5-year survival
70%

Relapse rate
33%

48%

50%

15%

78%

Strategies for the identification of genes contributing to phenotype
As genetics has already been shown to play a vital role in regulating self-renewal,
proliferation, differentiation, survival, and cell fate in hematopoiesis, and genetic
abnormalities can lead to hematological malignancies like AML, further investigation to
discover additional susceptibility genes is warranted. There are multiple ways in which
genetic susceptibility studies are performed. Traditional genome wide association studies
(GWAS), including traditional quantitative trait loci (QTL) mapping, and in silico
mapping based on single nucleotide polymorphisms (SNPs) are ways in which this can be
accomplished. Their power in doing so, however, differs.
GWAS typically compare two groups, a disease group and a normal group.
Genomic DNA is compared for selected markers of variation or SNPs. Genetic variations
that are more frequent in people with the disease are considered associated with the
disease. As these studies tend to point to broad genomic regions, researchers must use
other methods (such as DNA sequencing) to identify the exact genetic change involved in
the disease [31]. Traditional QTL mapping studies in mice are GWAS that are based on
the intercrossing of 2 strains of inbred mice that differ for the phenotype of interest. F1
generation mice are genetically identical to one another and are true hybrids of the
parental strains. F1 generation mice are then subject to brother-sister mating to form F2
generation mice, which are phenotypically and genotypically diverse. Phenotype and
genotype comparisons are made to identify which chromosomal loci correlate with the
particular phenotype studied. Traditional QTL mapping in mice may use backcrosses as
well [32]. Backcrossing involves the mating of F1 generation mice back to a parental
strain.
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SNP-based in silico mapping studies utilize known SNP information across the
genome to associate phenotypic data with available genetic information (genotypes).
However unlike traditional QTL studies, in silico mapping investigates several (≥25)
mouse strains. These comparisons allow the identification of chromosomal regions
containing genes responsible for the evaluated phenotype (Fig1.2). The recent availability
of denser marker sets (sets of known SNP information) has provided greater resolution
for this technique. Typical QTL studies have a 2-5cM resolution, whereas, in SNP based
in silico mapping studies, the relatively even spacing of the SNPs every 300kb allows for
mapping traits within 0.5cM regions [33]. SNP based in silico mapping makes
comparisons that are based on regions of the genome inherited from common ancestors
as opposed to traditional QTL studies that rely only on loci inherited from different
progenitors. Comparison across a greater number of strains provides greater statistical
power. In addition, SNP based in silico mapping takes into account a wider range of
phenotypic diversity by utilizing quantitative traits rather than traditional studies that only
take into account dichotomous (completely opposing) phenotypes, such as presenting
with a disease or without it. This type of haplotype associated mapping has successfully
proven to be more powerful in narrowing chromosomal locations containing genes of
interest than traditional QTL mapping in multiple studies [34, 35]. Table 1.2 summarizes
the differences in the two approaches.
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A
Region containing
gene of interest

Strain A

Strain B
phenotypically
different from A

Strain C

Strain D

phenotypically
different from A

phenotypically
different from A

Blue bar represents a particular chromosome
Red bar represents regions of the chromosome that are genetically different
from Strain A based on SNP data

B

Region containing
gene of interest

Strain A

Strain B
phenotypically
similar to A

Strain C

Strain D

phenotypically
similar to A

phenotypically
similar to A

Blue bar represents a particular chromosome
Red bar represents regions of the chromosome that are genetically different
from Strain A based on SNP data
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Figure 1.2: Hypothetical examples of how in silico comparisons are made.
Phenotypic similarities and differences are compared to SNP similarities and differences
among mouse strains to identify chromosomal regions of interest that control phenotype.
A. These comparisons take advantage of differences at SNP sites throughout the genome.
B. These comparisons take advantage of similarities at SNP sites throughout the genome.

Table 1.2: Comparison of genome wide mapping techniques in mice
Genetic diversity
Comparisons
Resolution

Traditional QTL
Utilizes 2 background strains
Differences of 2 progenitor strains
2-5cM

SNP Based In Silico
Utilizes ≥25 strains
Differences and similarities of ≥25 strains
0.5cM

Some of these strategies have been useful in identifying chromosomal loci
important to hematopoiesis. QTLs found for hematopoietic stem cell frequency have
been very large, in the range of 10 or more cMs, when using traditional QTL studies,
making it difficult to determine genes of importance [36-38]. One group identified 2
QTLs in regulating hematopoietic parameters in B6AKRF2 mice, which are derived
from intercrossing AKR and C57BL/6 mice. They found that a QTL in chromosome
12 regulated neutrophils in the blood and a QTL at chromosome 2 regulated stem
cell numbers in the bone marrow [39]. Interestingly, the gene Alpq1 was located in
this region. As you will find in chapter 2, our studies pointed to a region containing
Alpq3. These genes were both identified in GWAS for alcohol preference [40].
Chronic alcohol use induces bone loss through the suppression of Wnt signaling
[41]. Another group found a region in chromosome 2 important for response of
progenitors to early cytokines [38]. These studies were limited in that they only
investigated strains that were progeny of 2 background strains. This same group
10

investigated quantitative genetic variation in the hematopoietic stem cell and
progenitor cell compartment properties and found them to be associated with life
span QTLs [42]. Resolution in these studies was much lower than attainable by in
silico mapping. We show in chapter 2 that in silico mapping offers much higher
resolution for identifying these regions. Many regions in our study were much
smaller regions within the previously mentioned QTLs for hematopoietic stem and
early progenitor cell frequency.

Environment and hematopoiesis
Environmental influences have also been shown to influence hematopoiesis and
risk for hematological malignancies. Radiation, benzene, and cold exposure have been
shown to affect the process of hematopoiesis in a profound way [43-47]. Atomic bomb
survivors have a high incidence of myelodysplastic syndromes as well as AML [48].
Treatment of other diseases, such as other cancers and ankylosing spondylitis, with
radiation is also associated with these hematopoietic malignancies [49, 50]. Additionally,
prior to modern radiation safety precautions, radiologists had increased incidence of
AML and its precursors [51]. Benzene exposure also contributes to leukemia risk. It has
toxic effects on bone marrow, such that progenitor cell colony formation is significantly
declined with increasing benzene exposure [52]. Cold exposure has been shown to downregulate the expression of many genes encoding hematopoietic transcription factors
(Runx1, Scl, C-myb, and Gata-2) and particularly erythropoiesis related factors (Klfd,
Hbaa1, Ba1, Gata-1, Epo, and Epor). Some myelopoiesis related factors, however, were
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up-regulated in these low temperature conditions [47]. In chapters 3 and 4, we
demonstrate that the content of FAs in the diet control myeloid progenitor cell frequency.

Lipids and hematopoiesis
Studies for cancer prevention and treatment have in recent years turned to the diet
as it involves opportunities for natural ways to achieve these goals. Focus has centered on
FA consumption in the diet and how it affects cancer risk. Particular interest for
preventative measures as well as treatment options have focused on polyunsaturated fatty
acids (PUFAs).
FAs are carboxylic acids with hydrocarbon chains ranging from 4 to 28 carbons in
length and varying in their degree of saturation with hydrogen molecules. PUFAs are FAs
that contain more than one double bond. They are structural components of membrane
phospholipids and are the precursors to many signaling molecules. Omega-3 (n-3) and
omega-6 (n-6) are PUFAs in which the n-3 and n-6 refer to the placement of the first
double bond from the omega end of the FA chain (Fig1.3). n-3 FAs consist primarily of
-linolenic acid (ALA), eicosapentanoic acid (EPA), and docosahexanoic acid (DHA). In
several research studies, n-3 FAs have been found to have suppressive effects on cancer
[53-56]. n-6 FAs consist of linoleic acid (LNA) and arachidonic acid (ARA), among
others. In many studies, n-6 FAs appear to promote cancer development [53, 55, 57]. n-3
and n-6 FAs have antagonizing effects in the body. n-6 FA prostaglandins tend to be proinflammatory and pro-proliferative, while n-3 FA prostaglandins are associated with the
opposite qualities [58]. Suppression of n-6 FA-derived eicosanoids has been proposed as
a strategy for chemoprevention [59]. As n-3 FAs compete for the same metabolic
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enzymes as n-6 FAs, the ratio of n-3 to n-6 FAs in the diet is increasingly studied in
addition to the content of these FAs individually.

Figure 1.3: Examples of n-3 and n-6 fatty acids. A. Eicosapentanoic acid with first
double bond in n-3 position. B. Arachidonic acid with first double bond in n-6 position.

The broad category of lipids contains FAs among others. Lipids have function in
cell membranes, signaling, and energy storage. They have been shown to have several
effects on hematopoiesis. Prostaglandin E2 (PGE2), derived from ARA, preferentially
expands ST-HSCs/MPPs [60]. It also decreases macrophage colony stimulating factor
(M-CSF) production by bone marrow stromal cells [61]. Many studies have shown that
various lipoxygenases have key roles in regulating hematopoiesis as well [62-64].
Lipoxygenases are enzymes that catalyze the oxidation of PUFAs into
lipidhydroperoxides. Many lipoxygenase isozymes are involved in the metabolism of
eicosanoids. Recent studies have also investigated the functions of lysosomal acid lipase
in hematopoiesis. It has been shown to play a critical role in myelopoiesis during
hematopoietic development, differentiation, and homeostasis. Lysosomal acid lipase is a
key enzyme involved in cleaving cholesteryl esters and triglycerides. This cleavage
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generates free FAs and cholesterol in lysosomes. In lysosomal acid lipase knock out
mice, there is increased proliferation of HSCs and myeloid progenitor cells. The
microenvironment in these mice does not support normal hematopoiesis [65]. Valproic
acid, a clear liquid FA at room temperature, is also involved in control of hematopoiesis.
This histone deacetylase inhibitor is known to induce differentiation or apoptosis in
leukemic blast cells. It is also involved in HSC proliferation and enhances the potential of
interleukin 3 (IL-3) to stimulate megakaryopoiesis and erythropoiesis [66, 68].
A role for dietary lipids has been established in hematopoiesis. Ratios of n-3 to n6 FAs in the diet have been shown to have effects in prevention or progression
(depending on the ratio) of cancer [68, 69]. As progenitor cell frequency is important to
understanding leukemia progression, we decided to investigate how ratios of dietary n-3
to n-6 FAs affect stem and progenitor cell biology in myelopoiesis. In chapters 3 and 4
we show that these ratios indeed play a significant role in regulating myeloid progenitor
cell frequency.

Overall, this work proposes that genetic and environmental factors have related
roles in controlling myeloid progenitor cell frequency. In chapter 2, we propose that
genetic factors control hematopoiesis and that they can be identified by investigating
polymorphisms associated with the control of myeloid progenitor cell frequency among
inbred mouse strains. Our results suggest that genes that control metabolism and bone
properties regulate this process. In chapters 3 and 4, we show that the environmental
factor of the diet plays a significant role in controlling myeloid progenitor cell frequency.
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Collectively, this work supports the roles of dietary FA content, lipid metabolism, and
bone properties in regulating hematopoiesis.
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Abstract
Upon discovering that various strains of inbred mice have significantly different
myeloid progenitor cell pools, we hypothesized that polymorphisms between inbred
strains could be used to identify genes that regulate myeloid progenitor cell frequency in
the bone marrow. This information will be useful in understanding how hematopoietic
malignancies develop. We used hematopoietic progenitor cell assays, determining
progenitor cell frequency in 27 strains of inbred mice, and single nucleotide
polymorphism (SNP) based in silico mapping techniques to investigate our hypothesis.
These techniques returned several chromosomal loci containing cancer and hematological
disease related genes. Additionally, a control region containing interleukin 3 receptor
alpha (IL-3Rwhich is known to be involved in controlling myeloid progenitor cell
frequency, had a strong association with the regulation of this phenotype in these in silico
mapping studies. Upon meta-analysis of our data, we found that many chromosomal
regions that presented with strong association or as regions of interest contain genes
involved in bone formation, bone quality, and bone mechanics as well as lipid
metabolism and insulin metabolism. These genes of interest suggest a complex
combination of involvement in the properties of the bone specifically providing a support
mechanism for the regulation of myeloid progenitor cell frequency. Further investigation
of these genes may yield novel information as to how hematopoiesis is controlled, and
therefore why it may go awry in hematopoietic malignancies, such as acute myelogenous
leukemia.

22

Introduction
The process of hematopoiesis has been shown to depend on genetic and
environmental factors. Fatty acid (FA) composition of the diet, radiation exposure,
benzene exposure, and cold exposure are all environmental factors that affect this process
of blood cell development [1-6]. Several genes have also been shown to be involved in
controlling hematopoiesis. Stat, Gata, and Hox genes as well as Pu.1, Runx1, Scl, IL3R, and many more genes have been shown to regulate this process [7-13]. Stat-3 and
Stat-5 allow for survival and differentiation of myeloid hematopoietic cells [7]. Gata-1
and Pu.1 control hematopoietic cell fate by antagonizing one another [8]. Hox genes
control differentiation, proliferation, and cell fate during hematopoiesis [9-11]. Runx1 is a
master regulator of hematopoiesis [12]. Scl controls transcriptional programs during
embryonic hematopoiesis and is vital to megakaryocyte and erythrocyte development
[13-14]. Deletions in IL-3Rare known to cause decreased hematopoietic progenitor cell
frequency [15]. In our studies, we are continuing the search for genes involved in
controlling hematopoiesis.
Hematopoiesis is a process that occurs in a stepwise manner, beginning with
hematopoietic stem cells, continuing to develop into various stages of progenitor cells,
and finally becoming fully functional blood cells. In hematopoietic malignancies, such as
acute myelogenous leukemia (AML), this process is dysfunctional, allowing for the
expansion of the myeloid progenitor cell compartment. This compartment contains early
progenitors called granulocyte erythrocyte megakaryocyte macrophage (GEMM)
progenitors that have the potential to develop into several blood cell types. It contains
middle stage progenitors, such as granulocyte macrophage (GM) progenitors, that
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develop from GEMM progenitors. These middle stage progenitors have less potential
than their precursors. This compartment also contains late stage or committed
progenitors, such as erythrocyte (E), granulocyte (G), and macrophage (M) progenitors. E
progenitors also have GEMM progenitors as a precursor as well as a middle stage
precursor that cannot be assayed with our colony forming cell (CFC) technique. These
late stage progenitors, however, can only develop into erythrocytes, which have the
primary function of delivering oxygen to tissues throughout the body. G and M
progenitors develop from GM progenitors and only have the potential to develop into
granulocytes or macrophages, respectively. Granulocytes and macrophages are cells of
the immune system that defend against infection and foreign materials. Understanding
more completely how the processes of development and differentiation of these
progenitor cells are genetically controlled may provide valuable information as to how
they may malfunction in cancers of the blood and lymph.
Myeloproliferative diseases of the bone marrow are conditions that involve an
excess of progenitor cells of the myeloid lineage being produced. This precursor disease
may evolve into myelodysplastic syndrome or AML. Myelodysplastic syndromes are
bone marrow cell disorders in which the ineffective production of myeloid blood cells
increases risk for transformation to AML. In AML, normal bone marrow is overtaken by
immature functionless cells of the myeloid lineage, which causes a drop in normal blood
cells and platelets. Learning how hematopoietic cell frequency is controlled at the
progenitor cell level is vital to understanding why it becomes altered in these
hematological disorders.
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In order to determine how this process is genetically controlled, our lab used
hematopoietic progenitor cell assays and in silico mapping techniques to identify
chromosomal regions containing genes that control myeloid progenitor cell frequency
[16]. We have since increased the number of inbred strains studied from 10 to 27. We
also enhanced our assay to investigate the frequency of individual progenitor types. In
silico mapping databases have been improved to include increased sets of known SNP
information throughout the genome (denser marker sets) as well. This has increased
statistical power in our studies.

Materials and methods
Animals
All mice were purchased from The Jackson Laboratory (Bar Harbor, ME). Strains
include 129S1/SvImJ, A/J, AKR/J, BALB/cJ, BALB/cByJ, BTBRT+tf/J, C3H/HeJ,
C57BL/6J, C57BL/10J, C57BLKS/J, C57BR/cdJ, C57L/J, C58/J, CBA/J, DBA/1J,
DBA/2J, FVB/NJ, I/lnJ, LP/J, MA/MyJ, NZB/BINJ, NZW/lacJ, PERA/EiJ, PL/J,
SEA/GnJ, SM/J, and WSB/EiJ. Strains were chosen based on previously published
results [17]. Only male mice were used to avoid cyclic changes in hormones. Mice were
housed in the AAALAC accredited animal facilities of the Marshall University School of
Medicine. All animal use and care was approved by the Marshall University Institutional
Animal Care and Use Committee. Bone marrow was harvested at 10-14 weeks of age.
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Colony forming cell assays
CFC assays were performed upon bone marrow isolated from mice as previously
described [16, 18]. Briefly, bone marrow was harvested by flushing from the femurs with
Iscove’s Modified Dulbecco’s Medium (IMDM), and cells were counted and seeded in 4
well plates at a density determined empirically by a pilot study conducted with a broad
and consistent range of seeding densities. After linear response of colony production to
seeding density was ensured by the pilot study, seeding densities were chosen to produce
10-30 colonies for each well (4-well plates). Bone marrow was cultured in 1% semi-solid
Methocult M3434 (StemCell Technologies), supplemented with 0.4% autochthonous
sera. Cells were incubated for 6-7 days to allow colony formation. Colonies with a
minimum cell number of 20 were scored as positive using an inverted microscope at 40X
magnification. Colonies were counted based on morphological features that are
associated with each progenitor type.

In silico mapping
The SNPs used for genome-wide association tests are found in the Mouse
Diversity Array [19]. A total of 194,363 informative SNPs were used for SNPster and
efficient mixed model association (EMMA) analysis. Our data set was analyzed using
SNPster genome-wide association software (http://snpster.gnf.org), which gives a
phenotype/genotype correlation score in the form of -logp [17, 20]. These -logp scores
are used to identify regions of the genome that have a high probability of non-random
correlation. Heritability was measured based on standard deviation within the strains as
compared with the variability between strains. This measure of heritability is
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incorporated in the algorithms used in the analyses. Heritability is rated on a percentage
scale in which a higher percentage reflects a higher heritability. Figures and tables show logp values based on SNPster analysis. Based on the -logp value of the IL-3R control
region (3.02, p-value of 0.00095) and the need to minimize spurious associations, regions
with -logp values above 2.5 (p-value of 0.0032), were considered of interest, and regions
with a -logp value above 2.8 (p-value of 0.0016) were considered of strong association.
SNPster -logp values are not corrected for multiple comparisons.
We also employed the EMMA R package for genome-wide association scans as
an alternative to SNPster analysis. In this model, restricted maximum likelihood (REML)
was used to estimate the variance component, which is followed by a t-test. This method
accounts for strain relatedness to reduce the number of false positives [21].

Evaluation of Interleukin-3 Receptor Alpha
Genomic DNA was obtained from mouse liver. To amplify intron 7 of the murine
IL-3R gene, 100ng of genomic DNA from each strain and two primers (STP-44 and
STP-23) were used. The primers used were 5’-AACAGATTCCACCATGGCCTCC-3’
(STP-44) and 5’-TCTGACCTCGACTTGACCCGG-3’ (STP-23). PCR was performed by
31 cycles of 94°C for 1 minute, 53°C for 2 minutes, and 72°C for 3 minutes using
AmpliTaq Gold Faststart Polymerase (Applied Biosystems). PCR products were digested
with DdeI endonuclease (Promega) and analyzed on a 2% agarose gel using ethidium
bromide for detection of bands. A Mann Whitney test (using SigmaPlot) was performed
on genotypes A and B.
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Meta-analysis
For pathway analysis, we selected the top 50-55 genes within the chromosomal
regions with the highest -logp values from the in silico mapping analyses. We defined the
boundaries of the regions of interest as 90% of the highest -logp value in each peak.
Chromosomal regions were then entered into the Mouse Genome Information database to
determine the known genes that exist in the regions. The top 50 genes for each phenotype
were subjected to literature searches as well as Ingenuity Pathway Analysis v8.7 (IPA,
Ingenuity Systems Inc.) analyses to determine gene properties and network interactions.
IPA analyzes the combination of genes in signaling networks and statistically evaluates
the probability of the network against the probability that a network would form at
random. Networks are subject to a Fisher’s exact test, and those with p-values less than
0.001 were considered to be significant. Top 50-55 genes lists for each phenotype can be
found in the addendum.

Results
Our previous experiments in investigating the myeloid progenitor compartment in
multiple strains of inbred mice revealed that myeloid progenitor cell frequency varies
among strains [16]. Use of in silico mapping to compare these phenotypic similarities and
differences to the genetic similarities and differences among them was previously limited
due to a relatively low number of strains studied and less informative databases. To
increase the power and specificity of this technique, we have increased the amount of
strains being studied and refined our assay to study each progenitor type individually as
well as total progenitor cell frequency.
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In silico mapping utilizes SNP information across the genome to compare
phenotypic information to available genetic information about mouse strains. These
comparisons allow the identification of chromosomal regions containing genes
responsible for the evaluated phenotype. The availability of denser marker sets and an
increased number of strains being studied provided a greater statistical power for this
technique [19].
Twenty-seven mouse strains were evaluated for myeloid progenitor cell
frequency. These strains have varied ancestry, thus allowing in silico mapping techniques
to take advantage of closely related strains as well as strains that are more genotypically
diverse. The majority of mice were of Castle (129S1/SvImJ, A/J, AKR/J, BALB/cJ,
BALB/cByJ, C3H/HeJ, CBA/J, DBA/1J, DBA/2J, I/LnJ, LP/J, NZB/BINJ, NZW/lacJ,
SEA/GnJ, and SM/J) or C-57 related ancestry (C57BL/6J, C57BL/10J, C57BLKS/J,
C57BR/cdJ, C57L/J , C58/J, and MA/MyJ). Additional strains were of Swiss (FVB/NJ),
wild(PERA/EiJ and WSB/EiJ), other (PL/J), or unknown (BTBRT+tf/J) ancestry. There
was no correlation between ancestry and phenotypic data. GEMM, GM, G, M, and E
progenitor cell frequencies were evaluated as well as total myeloid progenitor cell
frequency. Phenotypic data was then compared to genotypic information using in silico
mapping.

Early progenitor frequency and in silico mapping
The earliest progenitor type evaluated by CFC assays was the GEMM progenitor.
This phenotype varied among inbred mouse strains, with a range of 0.005-0.449
colonies/1000 cells seeded, and an 89.8-fold difference between the strain with the
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highest progenitor cell frequency and the strain with the lowest progenitor frequency.
Phenotypic data for GEMM progenitor cell frequency is shown in Figure 2.1A as
colonies counted per 1000 cells seeded. In silico mapping revealed several regions with
-logp values above 2.5, and several regions with a -logp value above 2.8. In silico
mapping results using SNPster software are shown in Figure 2.1B. EMMA analysis was
also performed for this data. It showed similar results, with the region in chromosome 14
having significant genome wide association after tests for multiple comparisons. Table
2.1 shows chromosomal regions with -logp values above 2.5, and the genes that are
known to be located in those particular regions. Genes that are associated with leukemia
or known to be involved in hematopoiesis are shown in bold.
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Figure 2.1: Frequency of GEMM progenitor cells and in silico mapping. A: GEMM
progenitor cell frequency as measured by CFC assays. Results are shown as
colonies/1000 cells seeded. Error bars represent SEMs (n = 3-5). B: In silico mapping
results when phenotypic information from part A was compared with genotypic
information based on SNP information for the various inbred mouse strains. Results are
shown as a -logp value. Circles point out peaks with a -logp value above 2.5.
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Table 2.1: Genes of interest in regulating GEMM frequency
Genes located in chromosomal region with –logp values above 2.8
Gene
Ptprg, protein tyrosine phosphatase, receptor type, G
Cadps, Ca2+-dependent secretion activator
Fhit, fragile histidine triad gene
Rthyd3, resistance to thymic deletion 3
n-R5s45, nuclear encoded rRNA 5S 45
Synpr, synaptoporin
Atxn7, ataxin 7
Olfr720, olfactory receptor 720
Psmd6, proteasome (prosome, macropain) 26S subunit,
non-ATPase, 6
Thoc7, THO complex 7 homolog (Drosophila)
Rpl19-ps4, ribosomal protein L19, pseudogene 4
Sntn, sentan, cilia apical structure protein
Fezf2, Fez family zinc finger 2
Lrrc3b, leucine rich repeat containing 3B
Ngly1, N-glycanase 1
Oxsm, 3-oxoacyl-ACP synthase, mitochondrial
Rpl21-ps4, ribosomal protein L21, pseudogene 4
Iglon5, IgLON family member 5
Arhgap24, Rho GTPase activating protein 24
Tmc1m4, Tmc1 modifier 4
Appd2, APP associated premature death 2
Rpl31-ps3, ribosomal protein L31, pseudogene 3
Olfr721-ps1, olfactory receptor 721, pseudogene 1
Olfr31, olfactory receptor 31
Rarb, retinoic acid receptor, beta
Top2b, topoisomerase (DNA) II beta
Wbcq6, white blood cell quantitative locus 6
Nek10, NIMA (never in mitosis gene a)- related kinase 10
n-R5s44, nuclear encoded rRNA 5S 44
Il3ra, interleukin 3 receptor, alpha chain
Slc4a7, solute carrier family 4, sodium bicarbonate
cotransporter, member 7
Evi5, ecotropic viral integration site 5

Region
14: 12608073-12623845
14: 13451373-13528685
14: 10693745-10736604
14: 13387864-13423496
14: 13196426-13337728
14: 14291097-14489374
14: 14725638-15083409
14: 14725638-15083409

-logp value
4.309804
4
3.946922
3.928118
3.850781
3.793175
3.777284
3.777284

14: 14725638-15083409
14: 14725638-15083409
14: 14552540-14662129
14: 14290630-15106086
14: 13174979-13450378
14: 16103926-16294228
14: 17064860-17090557
14: 17064860-17090557
14: 12042049-12260227
7: 50735869-50778325
5: 102870089-102911460
5: 102870089-102911460
14: 17434991-17778674
14: 11970057-12401283
14: 15224397-15419224
14: 14162704-15177633
14: 17260939-17434727
14: 17260939-17434727
14: 17260939-17434727
14: 15683725-15737034
14: 9779720-9981564
14: 13985651-15492174

3.777284
3.777284
3.725843
3.671621
3.659556
3.518558
3.497573
3.497573
3.469801
3.354578
3.321482
3.321482
3.254926
3.219683
3.192465
3.162412
3.109579
3.109579
3.109579
3.084601
3.059484
3.024569

14: 11799713-15618059
5: 108163334-108178591

2.995591
2.818136

Genes located in chromosomal region with –logp values above 2.5
Gene
Ep400, E1A binding protein p400
Ptpn13, protein tyrosine phosphatase, non-receptor type
13
Idd21.1, insulin dependent diabetes susceptibility 21.1
Bmd8, bone mineral density 8
Efw, epididymal fat weight
Klhl8, kelch-like 8 (Drosophila)
Bmd39, bone mineral density 39
Tpi-rs9, triosephosphate isomerase related sequence 9
Ascc2, activating signal cointegrator 1 complex subunit 2
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Region
5: 111108675-111133204

-logp value
2.759341

5: 103855361-103866161
18: 78923250-78937776
6: 80953210-80967127
6: 80953210-80967127
5: 104324701-104326563
8: 118356974-118360978
14: 10871174-18415403
14: 9997616-18431455

2.71364
2.630284
2.614961
2.614961
2.600348
2.582694
2.569667
2.548268

The top region (-logp value of 4.3), located in chromosome 14, has a size of
15.8kbp. It contains protein tyrosine phosphatase, receptor type g (Ptprg), a known tumor
suppressor gene in mice and humans [22]. It is regulated by estrogen signaling and is
associated with control of peak bone mineral density in mice [23, 24]. The second region
(-logp value of 4.0), also located in chromosome 14, is 77.31kbp, and contains the gene
calcium2+-dependent secretion activator (Cadps). This gene’s expression is associated
with neuroendocrine tumors called pheochromocytomas, which may be malignant [25].
Cadps also has known function in controlling stability and recruitment of insulin granules
[26]. A third peak (-logp value of 3.9) also located in chromosome 14 spans 42.86kbp
and contains the fragile histidine triad gene (Fhit). This gene is a known tumor
suppressor with an aphidicolin-inducible fragile site (FRA3B) known for deletions that
are frequently observed in de novo acute leukemias [27]. Fhit is associated with type 2
diabetes and has been shown to inhibit prostaglandin E2 mediated cancer progression
[28, 29].

IL-3R genotyping as validation of technique
To validate the accuracy of our in silico mapping techniques, the region
containing interleukin 3 receptor alpha (IL-3R) presented as a significant region with a
-logp value of 3.02. This region was to serve as a positive control as it presented as a
region of interest in previous experiments in our laboratory. It is known to have a deletion
that eliminates the consensus sequence of branch points for RNA splicing [15].This
deletion causes aberrant splicing of IL-3R, which results in the production of a shorter
form of IL-3RThis form is not transported to the cell surface and therefore does not
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mediate actions of IL-3. In multiple strains of mice, this form of IL-3Ra, which contains
the 5bp deletion, reduces progenitor cell frequency [15]. We evaluated IL-3R in the 27
mouse strains for genotype based on a previously published method (Fig.2.2) [15]. IL3R can have two forms in mice. The A-type mice have a 5bp deletion, whereas the Btype mice do not. These genotypes were determined by PCR amplification of the region
of IL-3R including intron 7, which is the location of the branch-point deletion, followed
by DdeI endonuclease digestion to analyze A and B-type genes. DdeI cuts twice in the
wild-type intron 7 mice (type B) and only once in mutant intron 7 with the 5bp deletion
(type A). We compared this genotypic information to the phenotypic order (highest
progenitor cell frequency to lowest progenitor cell frequency) for the GEMM phenotype
(Table 2.2). The genotypic form A is found only in strains with low progenitor cell
frequencies. This finding is consistent with the idea that the A type of IL-3R is involved
in contributing to low progenitor cell frequency, and therefore served as a proper control
for our study. There are some strains with low progenitor cell frequency that are B-type
mice as well. This was anticipated as myeloid progenitor cell frequency is a complex
trait. A Mann Whitney test (using SigmaPlot) was performed on genotypes A and B. A
and B types of IL-3R were significantly different with a p-value of 0.0028.
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Figure 2.2: Genotype of IL-3R in mice. A. Type A has a 5bp deletion previously
shown to be associated with low progenitor cell frequency. DdeI restriction enzyme
digestion results in 2 bands for Type A and 3 bands for Type B IL-3R. B. Mouse liver
DNA was amplified using primers specific to IL-3Ra. PCR products were then digested
with DdeI and run on a 2% agarose gel to determine genotype. Asterisks denote type A
strains. A Mann Whitney test (using SigmaPlot) was performed on genotypes A and B.
A and B types of IL-3R were significantly different with a p-value of 0.0028.

Table 2.2: Comparison of GEMM phenotype and IL-3Ra genotype
Comparison of GEMM Phenotype and IL-3Ra
Genotype
Strain
LP/J
C57BLKS/J
DBA/2J
NZW/lacJ
PL/J
CBA/J
C57BR/cdJ
DBA/1J
C3H/HeJ
C57BL/10J
FVB/NJ
C57BL/6J
129S1/SvImJ
SEA/GnJ
C57L/J
PERA/EiJ
C58/J
SM/J
MA/MyJ
A/J
BALB/cJ
NZB/BINJ
I/LnJ
WSB/EiJ
BALB/cByJ
BTBRT+tf/J
AKR/J

GEMM Progenitor Cell Frequency
(Colonies/1000 Cells Seeded)
0.448718
0.363446
0.360417
0.306467
0.288063
0.273611
0.230556
0.220212
0.188523
0.152206
0.130556
0.114978
0.079167
0.077083
0.069031
0.068524
0.034921
0.034722
0.032044
0.03197
0.029405
0.024889
0.02375
0.022991
0.016964
0.011111
0.005
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Genotype
B
B
B
B
B
B
B
B
B
B
B
B
B
B
B
B
A
A
B
A
B
A
A
B
B
A
A

Middle-stage progenitor frequency and in silico mapping
A middle-stage progenitor type evaluated was the GM progenitor. This phenotype
varied among inbred mouse strains, with a range of 0-0.378 colonies/1000 cells seeded
and greater than a 147-fold difference in the strain with the highest progenitor cell
frequency and the strain with the lowest progenitor frequency (Fig.2.3A). In silico
mapping revealed one region with a -logp value above 2.8 and multiple regions with a logp value above 2.5. In silico mapping results using SNPster software are shown in
Figure 2.3B. Regions in chromosomes 14 and 15 were of genome wide significance after
correcting for multiple comparisons using EMMA analysis. Table 2.3 shows
chromosomal regions with -logp values above 2.5, and the genes that are known to be
located in those particular regions. Genes that are associated with leukemia or known to
be involved in hematopoiesis are shown in bold.
The top region for this phenotype spans 27.42kbp in chromosome 14 and contains
4 known genes: atherosclerosis 13 (Ath13), cocaine seizure 2 (Cosz2), plasma plant sterol
1 (plast1), and plasma plant sterol 1b (Plast1b). Ath13 is a gene found in an
atherosclerosis predisposition study using in silico QTL mapping [30]. Plant sterols
occur naturally in small quantities in vegetable oils and are also available as food
additives as they have cholesterol lowering properties [31]. In a genome wide association
study, Cosz2 was found to be associated with cocaine induced seizure thresholds [32].

37

Figure 2.3: Frequency of GM progenitor cells and in silico mapping. A: GM
progenitor cell frequency as measured by CFC assays. Results are shown as
colonies/1000 cells seeded. Error bars represent SEMs (n = 3-5). B: In silico mapping
results when phenotypic information from part A was compared with genotypic
information based on SNP information for the various inbred mouse strains. Results are
shown as a -logp value. Circles point out peaks with a -logp value above 2.5.
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Table 2.3: Genes of interest in regulating GM frequency
Genes located in chromosomal region with –logp values above 2.8
Gene
Ath13, atherosclerosis 13
Cosz2, cocaine seizure 2
Plast1, plasma plant sterol 1
Plast1b, plasma plant sterol 1b

Region
14: 63145626-63173054
14: 63145626-63173054
14: 63145626-63173054
14: 63145626-63173054

-logp value
2.889386
2.889386
2.889386
2.889386

Genes located in chromosomal region with –logp values above 2.5
Gene
Fbxl7, F-box and leucine-rich repeat protein 7
Defb43, defensin beta 43
Defb47, defensin beta 47

Region
15: 26533596-26539153
14: 63614409-63639344
14: 63614409-63639344

-logp value
2.705725
2.678805
2.678805

Late-stage progenitor frequency and in silico mapping
The late stage progenitor phenotypes (E, G, and M) varied among inbred mouse
strains, with ranges of 0.157-0.831, 0.190-0.653, and 0.239-1.055 cells/1000 cells seeded,
respectively (Fig. 2.4A, 2.5A, and 2.6A). Fold differences in the strain with the highest
progenitor cell frequency and the strain with the lowest progenitor frequency were 5.3fold in E, 3.4-fold in G, and 4.4-fold in M phenotypes. In silico mapping revealed
multiple regions in each with -logp values above 2.5. In silico mapping results using
SNPster software are shown in Figure 2.4B, 2.5B, and 2.6B. Tables 2.4, 2.5, and 2.6
show chromosomal regions with -logp values above 2.5, and the genes that are known to
be located in those particular regions. Genes that are associated with leukemia or known
to be involved in hematopoiesis are shown in bold.
The top region for E progenitor cell frequency is a 46.23kbp gene in chromosome
5 containing serine/threonine kinase 32b (Stk32b). This gene is associated with the
skeletal dysplasias of Ellis-van Creveld syndrome and Weyers acrodental dysostosis [33].
The top region for G progenitors is a 26.31kbp region in chromosome 11 containing the
genes, calcium/calmodulin-dependent protein kinase II beta (Camk2b) and YTK6
homolog (Ykt6). Group VIA phospholipase A2 forms a signaling complex with Camk2b
39

expressed in pancreatic islet beta-cells. This complex participates in insulin secretion.
Their expression is co-induced upon differentiation of pancreatic progenitor to endocrine
progenitor cells [34]. Ytk6 has been associated with tumor invasion and metastasis [35].
It is also known to mediate protein palmitoylation, the covalent attachment of FAs to
cysteine residues of membrane proteins [36]. Another region of significance for this
phenotype is a 6kbp region located in Chromosome 8. It contains the genes bone mineral
density 39 (Bmd39) and tetratricopeptide repeat domain 29 (Ttc29). Bmd39 contributes
to the degree to which bone tissues respond to mechanical loading [37]. Little is known
about Ttc29. The top region for M progenitors contains the gene Fhit, discussed above.
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Figure 2.4: Frequency of E progenitor cells and in silico mapping. A: E progenitor
cell frequency as measured by CFC assays. Results are shown as colonies/1000 cells
seeded. Error bars represent SEMs (n = 3-5). B: In silico mapping results when
phenotypic information from part A was compared with genotypic information based on
SNP information for the various inbred mouse strains. Results are shown as a -logp value.
Circles point out peaks with a -logp value above 2.5.
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Table 2.4: Genes of interest in regulating E frequency
Genes located in chromosomal region with –logp values above 2.8
Gene
Stk32b, serine/threonine kinase 32B

Region
5: 38038420-38084656

-logp value
2.849933

Genes located in chromosomal region with –logp values above 2.5
Gene
Ity2a, immunity to S. typhimurium 2a
Tcf7, transcription factor 7, T-cell specific
W6q3, weight 6 weeks QTL 3
Alpq3, alcohol preference QTL 3
Sc5d, sterol-C5-desaturase (fungal ERG3, delta-5desaturase) homolog (S. cerevisiae)
Crmp1, collapsin response mediator protein 1
Evc, Ellis van Creveld gene homolog (human)
Blmpf2, bleomycin-induced pulmonary fibrosis 2
Cia40, collagen induced arthritis 40
Ckdbp2, chronic kidney disease blood pressure locus 2
Pregq1, pregnancy QTL 1

Region
11: 52093205-52150216
11: 52093205-52150216
11: 52093205-52150216
9: 42048114-42065818
9: 42048114-42065818

-logp value
2.79202
2.79202
2.79202
2.728445
2.728445

5: 37681204-37711624
5: 37681204-37711624
11: 54038026-54056774
11: 54038026-54056774
11: 54038026-54056774
11: 54038026-54056774

2.690689
2.690689
2.532897
2.532897
2.532897
2.532897

Elnv, epilepsy naïve
Igan3, IgA nephropathy 3

9: 34385442-34401249
9: 34385442-34401249

2.527766
2.527766
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Figure 2.5: Frequency of G progenitor cells and in silico mapping. A: G progenitor
cell frequency as measured by CFC assays. Results are shown as colonies/1000 cells
seeded. Error bars represent SEMs (n = 3-5). B: In silico mapping results when
phenotypic information from part A was compared with genotypic information based on
SNP information for the various inbred mouse strains. Results are shown as a -logp value.
Circles point out peaks with a -logp value above 2.5.
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Table 2.5: Genes of interest in regulating G frequency
Genes located in chromosomal region with -logp values above 2.8
Gene
Camk2b, calcium/calmodulin-dependent protein
kinase II, 
Ykt6, YKT6 homolog (S. Cerevisiae)
Bmd39, bone mineral density 39
Ttc29, tetratricopeptide repeat domain 29

Region

-logp value

11: 5864894-5891207
11: 5864894-5891207
8: 80875682-80881683
8: 80875682-80881683

2.815092
2.815092
2.801206
2.801206

Genes located in chromosomal region with -logp values above 2.5
Gene
Erbb2ip, Erbb2 interacting protein
Tbqt5, tibia bone quality traits 5
Nln, neurolysin (metallopeptidase M3 family)
Srsf12, serine/arginine-rich splicing factor 12
Pou4f2, POU domain, class 4, transcription factor 2
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Region
13: 104665228-104684576
13: 104665228-104684576
13: 104701994-104824890
13: 104528844-104542789
8: 80947042-81014484

-logp value
2.794302
2.794302
2.694254
2.686086
2.613413

Figure 2.6: Frequency of M progenitor cells and in silico mapping. A: M progenitor
cell frequency as measured by CFC assays. Results are shown as colonies/1000 cells
seeded. Error bars represent SEMs (n = 3-5). B: In silico mapping results when
phenotypic information from part A was compared with genotypic information based on
SNP information for the various inbred mouse strains. Results are shown as a -logp value.
Circles point out peaks with a -logp value above 2.5.
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Table 2.6: Genes of interest in regulating M frequency
Genes located in chromosomal region with –logp values above 2.8
Gene
Fhit, fragile histidine triad gene

Region
14: 11584520-11656529

-logp value
2.94897

Genes located in chromosomal region with –logp values above 2.5
Gene
Ctrq2, C. trachomatis resistance QTL 2
Dkk2, dickkopf homolog 2 (Xenopus laevis)
Dym, dymeclin
Idd21.1, insulin dependent diabetes susceptibility 21.1
Pgis1, proteoglycan induced spondylitis 1
Bmd4, bone mineral density 4
Mob5, multigenic obesity 5
Plast2b, plasma plant sterol 2b
T2dm2sa, type 2 diabetes mellitus 2 in SMXA RI mice
Tmc1m1, Tmc1 modifier 1
Dclre1a, DNA cross-link repair 1A, PSO2 homolog (S.
cerevisiae)
Rpl21-ps4, ribosomal protein L21, pseudogene 4
Slit3, slit homolog 3 (Drosophila)
W6q3, weight 6 weeks QTL 3

Region
3: 131789521-131823292
3: 131789521-131823292
18: 75266222-75267209
18: 75266222-75267209
18: 75266222-75267209
15: 56618365-56626586
2: 110016970-110020628
2: 110016970-110020628
2: 110016970-110020628
2: 110016970-110020628

-logp value
2.714458
2.714458
2.693152
2.693152
2.693152
2.660179
2.655399
2.655399
2.655399
2.655399

19: 56596851-56621288
14: 12042049-12162496
11: 35100995-35120899
11: 35100995-35120899

2.587244
2.564197
2.520235
2.520235

Total progenitor frequency and in silico mapping
Total progenitor cell frequency varied among strains with a range of 0.855-2.933
colonies/1000 cells seeded and a 3.4 fold difference in the strain with the highest
progenitor cell frequency and the strain with the lowest progenitor frequency (Fig.2.7A).
In silico mapping results using SNPster software are shown in Figure 2.7B. Table 2.7
shows genes within regions that have -logp values above 2.5. Genes that are associated
with leukemia or known to be involved in hematopoiesis are shown in bold. Fhit and
Ptprg (genes found in regions of significance in other phenotypes) were located in the top
chromosomal regions for this phenotype.
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Figure 2.7: Frequency of total myeloid progenitor cells and in silico mapping. A:
Total progenitor cell frequency as measured by CFC assays. Results are shown as
colonies/1000 cells seeded. Error bars represent SEMs (n = 3-5). B: In silico mapping
results when phenotypic information from part A was compared with genotypic
information based on SNP information for the various inbred mouse strains. Results are
shown as a -logp value. Circles point out peaks with a -logp value above 2.5.
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Table 2.7: Genes of interest in regulating total progenitor cell frequency
Genes located in chromosomal region with –logp values above 2.5
Gene
Fhit, fragile histidine triad gene
Ptprg, protein tyrosine phosphatase, receptor type, G
Slit3, slit homolog 3 (Drosophila)
W6q3, weight 6 weeks QTL 3
n-R5s44, nuclear encoded rRNA 5S 44

Region
14: 11584520-11656342
14: 12838623-12859093
11: 35100995-35120899
11: 35100995-35120899
14: 9797430-9881986

-logp value
2.790107
2.629132
2.622682
2.622682
2.509633

IPA and literature searches reveal patterns among genes
In addition to confirming our results with the IL-3 R control, we performed a
meta-analysis of our data by entering the top 50-55 genes (as determined by
chromosomal region with the highest -logp values) for each phenotype into Ingenuity
Pathways Analysis (IPA) software. We used IPA to investigate the involvement of
signaling networks in the regulation of hematopoiesis to determine if there were patterns
of involvement in biological processes among these genes. Results indicate overlap of
signaling pathways throughout hematopoiesis, but also show that particular progenitor
types have genes working in pathways that are specific to their development. A summary
of this analysis can be found in Table 2.8. Top signaling pathways include cancer,
hematological disease, metabolism, development, cell cycle, cell growth and
proliferation, and cell death among others. As top signaling pathways include cancer,
hematological disease, genetic disorder, and many cancer related processes, this finding
further supports that our method can be used to identify potential tumor suppressors and
oncogenes in the regulation of hematopoiesis.
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Table 2.8: Top IPA signaling pathway for each phenotype.
IPA Top Signaling Networks
Phenotype

Signaling
Network 1
Cell Cycle,
Cardiovascular
System
Development
and Function,
Cellular
Development
Gene
Expression,
Cancer,
Hematological
Disease

Signaling
Network 2
Behavior,
Cardiovascular
Disease,
Cardiovascular
System
Development
and Function
Cell Death,
Cell-To-Cell
Signaling and
Interaction,
Cellular
Growth and
Proliferation

GM

Cancer,
Reproductive
System Disease,
Tumor
Morphology

E

Endocrine
System
Disorders,
Genetic
Disorder,
Metabolic
Disease

Lipid
Metabolism,
Carbohydrate
Metabolism,
Small
Molecule
Biochemistry
Cellular
Development,
Hematological
Disease,
Immunologica
l Disease

G

Lipid
Metabolism,
Molecular
Transport,
Small Molecule
Biochemistry

M

Cell
Morphology,
Neurological
Disease, Cell
Cycle

Total

GEMM

Signaling
Network 3
Cellular
Development,
Cellular Growth
and Proliferation

Signaling
Network 4

Signaling
Network 5

RNA Posttranscriptional
Modification,
Nervous System
Development and
Function,
Skeletal and
Muscular System
Development and
Function
Amino Acid
Metabolism,
Small Molecule
Biochemistry,
Cell Death

Lipid
Metabolism,
Small Molecule
Biochemistry,
Nucleic Acid
Metabolism

Cellular
Assembly and
Organization,
Cellular
Compromise,
DNA
Replication
Recombination
and Repair

Developmental
Disorder, Genetic
Disorder,
Embryonic
Development

Cancer,
Cardiovascular
Disease,
Cardiovascular
System
Development
and Function

Carbohydrate
Metabolism,
Small
Molecule
Biochemistry,
Drug
Metabolism

Cancer,
Reproductive
System, Genetic
Disorder

Cardiovascular
System
Development
and Function,
Skeletal and
Muscular
System
Development
and Function,
Cell
Morphology

Cellular
Compromise,
Carbohydrate
Metabolism,
Molecular
Transport

Organismal
Injury and
Abnormalities,
Genetic Disorder,
Hepatic System
Disease
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Cancer,
Cardiovascular
System
Development
and Function,
Cell Cycle
Genetic
Disorder ,
Metabolic
Disease,
Connective
Tissue
Development
and Function

As IPA was limited in recognizing genes that relatively little is known about in
signaling pathways, we also conducted literature searches using PubMed to understand
more about the patterns among these top genes. For example, bone mineral density genes,
bone quality genes, and many genes related to other bone properties are not recognized in
signaling pathways in IPA, yet they make up 18% of the genes in our meta-analysis.
Results for these literature searches can be found in Table 2.9. In the literature searches
conducted, we found that 11% of genes in our listing for the top 50 genes in each
phenotype are known to be associated with the regulation of hematopoiesis. Thirty
percent of genes are known to be associated with cancer. Of these, there seems to be a
mix of genes related to many cancer processes and types. As progenitor cell frequency is
related to AML and its precursors, it is not surprising that 15% of genes returned on the
top genes lists are previously known to be involved in leukemias specifically. Taken
together, these data also support our use of these techniques to identify tumor suppressors
and oncogenes in hematopoietic regulation. In addition, 18% of the top genes are
involved in bone properties, 20% are related to FA, fat, or atherosclerosis, and 19% are
related to insulin or diabetes. Of the genes in these top genes lists, several have been
shown to be involved in regulating hematopoiesis or contributing to leukemia (shown in
bold), whereas most are novel candidate genes for these processes.
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Table 2.9: Genes located in regions with highest -logp values associated with
relevant processes/qualities.
Genes located in regions with highest -logp values associated with relevant
processes/qualities

Cancer (30%)

Leukemia (15%)

Hematopoiesis (11%)

Bone Properties (18%)

Fatty acid, Fat, or
Atherosclerosis (20%)

Insulin or Diabetes (19%)

Cadps, Top2b, Rarb, Ep400, Ptpn13, Net1, Ikbkap, Skts-fp1, Fbxl7, Ints6,
Ctsb, Scara5, Msra, Gata4, Pou6f1, Blk, Dleu2, Kcnrg, Mir15a, Mir16-1,
Trim13, Elp3, Neil2, Tdh, Tcf7, Crmp1, Ptprt, Cbx5, Smug1, Slc22a4,
Cinda3, Stx18, Flt1, Slit3, Ykt6, Erbb2ip, Nln, Mpped2, Opcml, Rgs4,
Adamts6, Slc13a1, Hcn1, Dkk2, Dym, Afap1l2, ,Vwa2, Lrrk2, Slc2a13,
Myo5b, Dcc, Casp7, Fat1, Mtnr1a, Lama1, Ptprg, Evi5, Nek10, Slc4a7,
Sntn, Wasl, Fhit, Lrrc3b, Psmd6
Il3ra, Ptpn13, Gata4, Blk, Dleu2, Mir15a, Mir16-1, Trim13, Tcf7, Cbx5,
Slc22a4, Flt1, Rgs4, Dcc, Casp7, Evi5, Wasl, Fhit, Rarb, Top2b, Net1,
Ctsb, Kcnrg, Crmp1, Ptprt, Erbb2ip, Slc13a1, Lrrk2, Lama1, Lrrc3b,
Arhgap24, Camk2b, F11
Il3ra, Ep400, Ptpn13, Gata4, Blk, Dleu2, Mir15a, Mir16-1, Trim13, Tcf7,
Cbx5, Slc22a4, Flt1, Rgs4, Dcc, Casp7, Evi5, Wasl, Fhit, Jakmip1, Ptprg,
Rarb, Wbcq6
Slc22a4, Rgs4, Dcc, Casp7, Wasl, Fhit, Slc13a1, Lama1, Dkk2, Dym,
Bmd8, Bmd39, Bmd3, Bmch2, Bmd4, Bmd5, Bmd7, Evc2, Tbqt5, Bmd1,
Evc, Pgis1, Ptprg, Mir199a-1, Tcf7, Blk, Rarb, Stk32b, Il3ra, Net1, Ctsb,
Agnm2, Bdlnq7, Flt1, Fezf2, Pou4f2, Gata4, Dcdc5, Ptpn13
Slc22a4, Rgs4, Dcc, Casp7, Wasl, Fhit, Ptprg, Blk, Rarb, Il3ra, Ctsb, Flt1,
Gata4, Erbb2ip, Camk2b, F11, Ikbkap, Msra, Tdh, Ykt6, Hcn1, Fat1,
Oxsm, Plast1, Plast1b, Lmbrd1, Sc5d, Plast2b, Tcf7, Dleu2, Ptprt, Myo5b,
Mtnr1a, Efw, Mob5, T2dm2sa, Dkk2, Bmd8, Scara5, Ath8, Ath13, Mtmr9,
Xkr6, Dnm2, Ascc2
Slc22a4, Rgs4, Dcc, Casp7, Wasl, Blk, Ctsb, Flt1, Gata4, F11, Ikbkap,
Msra, Plast1, Plast1b, Tcf7, Dleu2, Myo5b, Mtnr1a, Efw, Mob5, T2dm2sa,
Fhit, Camk2b, Tdh, Hcn1, Lama1, Crmp1, Pou4f2, Ptpn13, Cadps, Ints6,
Pou6f1, Vwa2, Idd21.1, Fam167a, Ap2a1, Idd26, Athsq1, Bglu1, Aod2,
Idd21.2

Discussion
The strength of in silico mapping method over more traditional methods is evident
as it provides denser marker sets and makes comparisons that are based on regions of the
genome inherited from common ancestors, as opposed to traditional quantitative trait loci
(QTL) studies that rely only on loci inherited from different progenitors. Comparison
across a greater number of strains also provides greater statistical power. This type of
haplotype associated mapping has successfully proven to be more powerful in narrowing
chromosomal regions of interest than traditional QTL mapping in multiple studies [38,
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39]. This method has been confirmed to identify chromosomal regions containing genes
that are known to be associated with the particular phenotype [19]. This was evident in
our study as well, as the region of chromosome 14 containing IL-3R presented with a
high -logp value. The region containing IL-3R was a control for our study. IL-3Ris
mutated in multiple inbred mouse strains causing their progenitor cell frequencies to be
reduced.
Our results pointed to regions identified in previous QTL studies, while providing
greater resolution. Henckaerts et al. [40] found that the following QTLs are of importance
to the hematopoietic progenitor cell compartment: chromosome 4(37.6-48.5 and 6678.5cM), chromosome 2(72.1-77.2cM), chromosome 9(23-27cM), and chromosome 14
(broad range). We found that chromosome 4(42.13-45.76cM) contains genes that overlap
with the previous QTL study. These genes are autoimmune glomerulonephritis in MRL 2
(Agnm2) and bone mineral density (Bmd7). They are contained within a region important
to granulocyte progenitor cell frequency. Chromosome 4(74.75-75.77cM) contains the
overlapping genes of atherosclerosis susceptibility QTL 1(Athsq1), cytokine induced
activation 3(Cinda3), and forkhead-associated phosphopeptide binding domain 1
(Fhad1), in a region that is important to progenitor cell frequency in erythrocyte, and
total frequency phenotypes. Chromosome 2(80.93-85.27) contains one overlapping gene,
spontaneous crescentic glomerulonephritis QTL 3(Scgq3). Chromosome 9(23.57cM)
contains the overlapping gene, sterol-C5-desaturase (Sc5d), in a region that is important
to erythrocyte development. We also found several very significant regions within
chromosome 14. Henckaerts et al. [41] also found that a region of chromosome 2 is
important to stem and progenitor cell populations. They found that the region at 73.2-
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77.2cM in chromosome 2 is a QTL for early hematopoietic populations. We found a
region of chromosome 2 at 80.92-80.96cM that contains genes that overlap the previously
discovered QTL. Another group found that a QTL at chromosome 2 regulates stem cell
numbers in the bone marrow [42]. Interestingly, the gene alcohol preference QTL 1
(Alpq1) was located in this region. Our studies resulted in a region of chromosome
9(20.76cM) containing alcohol preference QTL 3 (Alpq3). These were both identified in
genome wide association studies for alcohol preference [43]. Chronic alcohol use induces
bone loss through the suppression of Wnt signaling [44].
Additionally, a portion of mouse chromosome 11 that presented in the E
progenitor phenotype from our study corresponds to human chromosome 5, specifically
region 5q31.1. This particular region of chromosome 5 undergoes deletion in 5qsyndrome, which is a disorder that affects bone marrow cells and causes severe
macrocytic anemia and myelodysplastic syndromes that may lead to AML. It is
characterized by a defect in erythroid differentiation and is often accompanied by
erythroid hypoplasia in the bone marrow [45]. It is fitting that this region presented in the
E progenitor phenotype. This result further validates our methods. Genes contained in the
region are transcription factor 7 (Tcf7), CDC42 small effector 2 (Cdc42se2), follistatinlike 4 (Fstl4), Rap guanine nucleotide exchange factor 6 (Rapgef6), and solute carrier
family 22 member 4 (Slc22a4).
Our meta-analysis of the top 50-55 genes within the chromosomal regions with
the highest -logp values for each phenotype revealed interesting patterns. Overall, there
were 39 genes associated with bone mineral density, bone quality, bone mechanics, and
bone disease. These genes are located in several different chromosomal regions. Seven of
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these were bone mineral density genes: Bmd1, Bmd3, Bmd4, Bmd5, Bmd7, Bmd8, and
Bmd39. Bone mechanical trait 2 (Bmch2) also showed up in our meta-analysis as well as
tibia bone quality trait 5 (Tbqt5). Several additional genes were involved in osteogenesis,
skeletal formation, bone morphogenic signaling, osteoclast differentiation, osteoblast
differentiation, skeletal size, bone growth plate regulation, and bone disease [46-55]. This
finding suggests a role of bone properties in determining how myeloid cells develop.
Additional support for the idea of bone properties being key regulators of myeloid
progenitor cell frequency lies in the high number of genes related to calcium and estradiol
signaling that were located in chromosomal regions of high -logp values as well. The
roles of calcium and estradiol in the quality of bone have been well documented. [56-62]
Another interesting pattern involved metabolism. Twenty percent of the genes
returned in our analysis were related to FA uptake and oxidation, lipid metabolism, and
atherosclerosis susceptibility [63-70]. This finding supports our previous work that shows
that the ratio of omega 3 to omega 6 FAs in the diet has a significant effect on progenitor
cell frequency in the bone marrow of mice [11]. Furthermore, these qualities have been
shown to regulate bone mineral density in humans and mice. High fat diets lower bone
mineral density and bone volume [69, 61]. One study also correlates QTLs for body size
(body weight, length, and adipose mass) with those identified for skeletal traits,
suggesting that many QTLs may regulate bone properties via their effect on body size
[72].
Genes associated with glucose metabolism, insulin, and diabetes susceptibility
were also present in high numbers in our meta-analysis. These genes have been show to
have a major role in bone remodeling and metabolism. Osteoblasts express insulin
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receptors and favor glucose metabolism through the hormone osteocalcin. Insulin
signaling in osteoblasts is necessary for whole-body glucose homeostasis because it
increases osteocalcin activity. Osteoclasts can determine the status and function of
osteocalcin and, accordingly, increase or decrease insulin signaling in osteoblasts. This
determination then promotes or hampers glucose metabolism in a bone resorptiondependent manner in mice and humans [73]. As insulin stops the use of fat as an energy
source, lack of control of insulin levels can have a profound effect on fat stores in the
body. Insulin’s direct effect on FA synthesis in the body could play a role in the bone
properties associated with fat as well. Furthermore, insulin receptor interacting proteins
have been shown to regulate hematopoietic stem and progenitor cell pools [74].
Future directions for our lab include determining if the genes located in these
chromosomal regions with high -logp values are in fact associated with changes in
myeloid progenitor cell frequency. In order to complete this work, we will investigate
these novel candidate genes one by one, beginning with those in which nucleotides
correlate strongly with phenotypic data and are involved in the processes that our data
suggest are regulators of hematopoiesis. We will test these genes for function in
hematopoiesis by altering their expression. We will also determine if the particular
pathways that emerged the most (bone properties and metabolic processes) are
biomarkers for AML progression risk. Additionally, we will validate the role of these
genes and pathways in human hematopoiesis and AML progression.
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GEMM top genes list
Gene

Region

-logp value

Ptprg, protein tyrosine phosphatase, receptor type, G
Cadps, Ca2+-dependent secretion activator
Fhit, fragile histidine triad gene
Rthyd3, resistance to thymic deletion 3
n-R5s45, nuclear encoded rRNA 5S 45
Synpr, synaptoporin
Atxn7, ataxin 7
Olfr720, olfactory receptor 720
Psmd6, proteasome (prosome, macropain) 26S subunit, non-ATPase, 6
Thoc7, THO complex 7 homolog (Drosophila)
Rpl19-ps4, ribosomal protein L19, pseudogene 4
Sntn, sentan, cilia apical structure protein
Fezf2, Fez family zinc finger 2
Lrrc3b, leucine rich repeat containing 3B
Ngly1, N-glycanase 1
Oxsm, 3-oxoacyl-ACP synthase, mitochondrial
Rpl21-ps4, ribosomal protein L21, pseudogene 4
Iglon5, IgLON family member 5
Arhgap24, Rho GTPase activating protein 24
Tmc1m4, Tmc1 modifier 4
Appd2, APP associated premature death 2
Rpl31-ps3, ribosomal protein L31, pseudogene 3
Olfr721-ps1, olfactory receptor 721, pseudogene 1
Olfr31, olfactory receptor 31
Rarb, retinoic acid receptor, beta
Top2b, Topoisomerase (DNA), beta II
Wbcq6, white blood cell quantitative locus 6
Nek10, NIMA (never in mitosis gene a)- related kinase 10
n-R5s44, nuclear encoded rRNA 5S 44
Il3ra, interleukin 3 receptor, alpha chain
Slc4a7, solute carrier family 4, sodium bicarbonate cotransporter,
member 7
Evi5, ecotropic viral integration site 5
Ep400, E1A binding protein p400
Ptpn13, protein tyrosine phosphatase, non-receptor type 13
Idd21.1, insulin dependent diabetes susceptibility 21.1
Bmd8, bone mineral density 8
Efw, epididymal fat weight
Klhl8, kelch-like 8 (Drosophila)
Bmd39, bone mineral density 39
Tpi-rs9, triosephosphate isomerase related sequence 9
Ascc2, activating signal cointegrator 1 complex subunit 2
Caln1, calneuron 1
Vmn2r62, vomeronasal 2, receptor 62
Bmd3, bone mineral density 3
Tyw1, tRNA-yW synthesizing protein 1 homolog (S. cerevisiae)
Net1, neuroepithelial cell transforming gene 1
Noc4l, nucleolar complex associated 4 homolog (S. cerevisiae)
Ath8, atherosclerosis 8
Bmch2, bone mechanical trait 2
Ctrcts, cataract severity
Ikbkap, inhibitor of kappa light polypeptide enhancer in B-cells, kinase
complex-associated protein
Skts-fp1, skin tumor susceptibility in FVB and PWK 1

14: 12608073-12623845
14: 13451373-13528685
14: 10693745-10736604
14: 13387864-13423496
14: 13196426-13337728
14: 14291097-14489374
14: 14725638-15083409
14: 14725638-15083409
14: 14725638-15083409
14: 14725638-15083409
14: 14552540-14662129
14: 14290630-15106086
14: 13174979-13450378
14: 16103926-16294228
14: 17064860-17090557
14: 17064860-17090557
14: 12042049-12260227
7: 50735869-50778325
5: 102870089-102911460
5: 102870089-102911460
14: 17434991-17778674
14: 11970057-12401283
14: 15224397-15419224
14: 14162704-15177633
14: 17260939-17434727
14: 17260939-17434727
14: 17260939-17434727
14: 15683725-15737034
14: 9779720-9981564
14: 13985651-15492174

4.309804
4
3.946922
3.928118
3.850781
3.793175
3.777284
3.777284
3.777284
3.777284
3.725843
3.671621
3.659556
3.518558
3.497573
3.497573
3.469801
3.354578
3.321482
3.321482
3.254926
3.219683
3.192465
3.162412
3.109579
3.109579
3.109579
3.084601
3.059484
3.024569

14: 11799713-15618059
5: 108163334-108178591
5: 111108675-111133204
5: 103855361-103866161
18: 78923250-78937776
6: 80953210-80967127
6: 80953210-80967127
5: 104324701-104326563
8: 118356974-118360978
14: 10871174-18415403
14: 9997616-18431455
5: 130890171-130891984
7: 50006469-50091657
13: 3190342-3242611
5: 130758991-130829540
13: 3876452-3899689
5: 111079377-111080089
4: 56766913-56778159
4: 56766913-56778159
4: 56766913-56778159

2.995591
2.818136
2.759341
2.71364
2.630284
2.614961
2.614961
2.600348
2.582694
2.569667
2.548268
2.488252
2.453735
2.450389
2.431364
2.418577
2.409792
2.406824
2.406824
2.406824

4: 56766913-56778159
4: 56766913-56778159

2.406824
2.406824
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GM top genes list
Gene

Region

-logp value

Ath13, atherosclerosis 13
Cosz2, cocaine seizure 2
Plast1, plasma plant sterol 1
Plast1b, plasma plant sterol 1b
Fbxl7, F-box and leucine-rich repeat protein 7
Defb43, defensin beta 43
Defb47, defensin beta 47
Fam124a, family with sequence similarity 124, member A
Atp8a2, ATPase, aminophospholipid transporter-like
Ints6, integrator complex subunit 6
Serpine3, serpin peptidase inhibitor, member 3
Ctsb, cathepsin B
Scara5, scavenger receptor class A, member 5 (putative)
Fbxo16, F-box protein 16
Zfp395, zinc finger protein 395
Gucy1b2, guanylate cyclase 1, soluble, beta 2
Msra, methionine sulfoxide reductase A
Prss51, protease, serine, 51
Prss52, protease, serine, 52
Prss55, protease, serine, 55
Zfp658, zinc finger protein 658
Zfp719, zinc finger protein 719
Zfp819, zinc finger protein 819
Gata4, GATA binding protein 4
Bmd4, bone mineral density 4
Pou6f1, POU domain, class 6, transcription factor 1
Blk, B lymphoid kinase
Fam167a, family with sequence similarity 167, member A
Dleu2, deleted in lymphocytic leukemia, 2
Kcnrg, potassium channel regulator
Mir15a, microRNA 15a
Mir16-1, microRNA 16-1
Trim13, tripartite motif-containing 13
Elp3, elongation protein 3 homolog (S. cerevisiae)
Kif13b, kinesin family member 13B
Arhgap6, Rho GTPase activating protein 6
Bmd5, bone mineral density 5
Bwq7, body weight, QTL 7
Scgq2, spontaneous crescentic glomerulonephritis QTL 2
Mtmr9, myotubularin related protein 9
Neil2, nei like 2 (E. coli)
Tdh, L-threonine dehydrogenase
Xkr6, X Kell blood group precursor related family member 6
Ap2a1, adaptor protein complex AP-2, alpha 1 subunit
Iglon5, IgLON family member 5
Cadps, Ca2+-dependent secretion activator
Defb30, defensin beta 30
Defb42, defensin beta 42
Defb48, defensin beta 48
Fecq3, fecundity QTL 3
Idd26, insulin dependent diabetes susceptibility 26
Lmbrd1, LMBR1 domain containing 1

14: 63145626-63173054
14: 63145626-63173054
14: 63145626-63173054
14: 63145626-63173054
15: 26533596-26539153
14: 63614409-63639344
14: 63614409-63639344
14: 63139934-63190101
14: 60475030-60613198
14: 63310514-63363750
14: 63310514-63363750
14: 63696395-63747802
14: 66279212-66323155
14: 65923363-66010722
14: 65923363-66010722
14: 63073236-63133525
14: 64700581-64935824
14: 64700581-64935824
14: 64700581-64935824
14: 64700581-64935824
7: 50806886-50879931
7: 50806886-50879931
7: 50806886-50879931
14: 63819697-63990229
15: 100386574-100411741
15: 100386574-100411741
14: 63813790-64091361
14: 63813790-64091361
14: 62190971-62280557
14: 62190971-62280557
14: 62190971-62280557
14: 62190971-62280557
14: 62190971-62280557
14: 66148441-66169246
14: 65347007-65376483
X: 165319571-165322740
1: 123019155-123039644
1: 123019155-123039644
1: 123019155-123039644
14: 63809198-64260649
14: 63809198-64260649
14: 63809198-64260649
14: 63809198-64260649
7: 52178097-52178425
7: 50738756-50775032
14: 13505483-13522770
14: 63593927-63750325
14: 63593927-63750325
14: 63593927-63750325
1: 24822648-24829896
1: 24822648-24829896
1: 24822648-24829896

2.889386
2.889386
2.889386
2.889386
2.705725
2.678805
2.678805
2.470732
2.462052
2.459213
2.459213
2.425771
2.423693
2.420556
2.420556
2.408946
2.394743
2.394743
2.394743
2.394743
2.296665
2.296665
2.296665
2.290406
2.286494
2.286494
2.254468
2.254468
2.233419
2.233419
2.233419
2.233419
2.233419
2.214623
2.193357
2.180174
2.144574
2.144574
2.144574
2.144055
2.144055
2.144055
2.144055
2.142233
2.120025
2.101804
2.09575
2.09575
2.09575
2.093422
2.093422
2.093422
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E top genes list
Gene

Region

-logp value

Stk32b, serine/threonine kinase 32B
Ity2a, immunity to S. typhimurium 2a
Tcf7, transcription factor 7, T-cell specific
W6q3, weight 6 weeks QTL 3
Alpq3, alcohol preference QTL 3
Sc5d, sterol-C5-desaturase
Crmp1, collapsin response mediator protein 1
Evc, Ellis van Creveld gene homolog (human)
Blmpf2, bleomycin-induced pulmonary fibrosis 2
Cia40, collagen induced arthritis 40
Ckdbp2, chronic kidney disease blood pressure locus 2
Pregq1, pregnancy QTL 1
Elnv, epilepsy naïve
Igan3, IgA nephropathy 3
Athsq1, atherosclerosis susceptibility QTL 1
Bmd7, bone mineral density 7
Cytl1, cytokine-like 1
Synj1, synaptojanin 1
Bdlnq7, body length QTL 7
Bglu1, blood glucose level 1
Mob5, multigenic obesity 5
Prdt2, prion disease incubation time 2
Scgq3, spontaneous crescentic glomerulonephritis QTL 3
Cdc42se2, CDC42 small effector 2
Fstl4, follistatin-like 4
Evc2, Ellis van Creveld syndrome 2 homolog (human)
Arsj, arylsulfatase J
Ctrq2, C. trachomatis resistance QTL 2
Rapgef6, Rap guanine nucleotide exchange factor (GEF) 6
Ptprt, protein tyrosine phosphatase, receptor type, T
Jakmip1, janus kinase and microtubule interacting protein 1
Chd6, chromodomain helicase DNA binding protein 6
Fhit, fragile histidine triad gene
Bmd4, bone mineral density 4
Cbx5, chromobox homolog 5 (Drosophila HP1a)
Smug1, single-strand selective monofunctional uracil DNA
glycosylase
Slc22a4, solute carrier family 22, member 4
Tbqt5, tibia bone quality traits 5
Alan2, alloantigen response 2
Cinda3, cytokine induced activation 3
Stx18, syntaxin 18
Lrrc3b, leucine rich repeat containing 3B
Ath13, atherosclerosis 13
Plast1, plasma plant sterol 1
Plast1b, plasma plant sterol 1b
Flt1, FMS-like tyrosine kinase 1
Slit3, slit homolog 3 (Drosophila)
Ptprg, protein tyrosine phosphatase, receptor type, G
Aaom1, autoimmune aoritis in MRL mice 1
Pregq4, pregnancy QTL 4

5: 38038420-38084656
11: 52093205-52150216
11: 52093205-52150216
11: 52093205-52150216
9: 42048114-42065818
9: 42048114-42065818
5: 37681204-37711624
5: 37681204-37711624
11: 54038026-54056774
11: 54038026-54056774
11: 54038026-54056774
11: 54038026-54056774
9: 34385442-34401249
9: 34385442-34401249
4: 142154832-142171686
4: 142154832-142171686
5: 38104702-38133786
16: 90991665-91012590
2: 160241262-160460912
2: 160241262-160460912
2: 160241262-160460912
2: 160241262-160460912
2: 160241262-160460912
11: 54532428-54574973
11: 52789869-52808156
5: 37676733-37736901
3: 126107801-126111371
3: 126107801-126111371
11: 54492977-54520054
2: 162384520-162390034
5: 37515261-37745440
2: 160787704-160857202
14: 10402891-10416373
15: 102961141-103060839
15: 102961141-103060839

2.849933
2.79202
2.79202
2.79202
2.728445
2.728445
2.690689
2.690689
2.532897
2.532897
2.532897
2.532897
2.527766
2.527766
2.46515
2.46515
2.435442
2.432217
2.431364
2.431364
2.431364
2.431364
2.431364
2.416867
2.368597
2.344392
2.298671
2.298671
2.28537
2.284619
2.280844
2.279515
2.251435
2.251233
2.251233

15: 102961141-103060839
11: 53799692-53822305
13: 107080581-107145390
4: 141979409-141982891
4: 141979409-141982891
5: 38259984-38490902
14: 16181610-16207728
14: 101291502-101501656
14: 101291502-101501656
14: 101291502-101501656
5: 148421156-148422167
11: 35100995-35120899
14: 12383660-12401283
4: 141360892-141385435
17: 67731385-67741554

2.251233
2.250217
2.241795
2.240757
2.240757
2.22981
2.217484
2.215726
2.215726
2.215726
2.200029
2.197969
2.193588
2.187286
2.172943
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Region

-logp value

Camk2b, calcium/calmodulin-dependent protein kinase II, 
Ykt6, YKT6 homolog (S. Cerevisiae)
Bmd39, bone mineral density 39
Ttc29, tetratricopeptide repeat domain 29
Erbb2ip, Erbb2 interacting protein
Tbqt5, tibia bone quality traits 5
Nln, neurolysin (metallopeptidase M3 family)
Srsf12, serine/arginine-rich splicing factor 12
Pou4f2, POU domain, class 4, transcription factor 2
Bmd3, bone mineral density 3
Mob5, multigenic obesity 5
Mpped2, metallophosphoesterase domain containing 2
Plast2b, plasma plant sterol 2b
T2dm2sa, type 2 diabetes mellitus 2 in SMXA RI mice
Tmc1m1, Tmc1 modifier 1
Slc10a7, solute carrier family 10, member 7
Rbmxrt, RNA binding motif protein, retrogene
Scgq2, spontaneous crescentic glomerulonephritis QTL 2
Bmd5, bone mineral density 5
Sxbq2, SGC/Knj cross B6 QTL 2
Ath13, atherosclerosis 13
Cosz2, cocaine seizure 2
Plast1, plasma plant sterol 1
Plast1b, plasma plant sterol 1b
Svtms, survival time modifier of Sod2
Opcml, opioid binding protein/cell adhesion molecule-like
Bmd1, bone mineral density 1
Rgs4, regulator of G-protein signaling 4
Scgq1, spontaneous crescentic glomerulonephritis QTL 1
Sle16, systematic lupus erythematosus susceptibility 16
Adamts6, a disintegrin-like and metallopeptidase
Slc13a1, solute carrier family 13, member 1
Nacad, NAC alpha domain containing
Snora5c, small nucleolar RNA, H/ACA box 5C
Tbrg4, transforming growth factor beta regulated gene 4
Kcnip1, Kv channel-interacting protein 1
W6q3, weight 6 weeks QTL 3
Dnm2, dynamin 2
Mir199a-1, microRNA 199a-1
Hcn1, hyperpolarization-activated, cyclic nucleotide-gated K+ 1
Plekha5, pleckstrin homology domain containing, member 5
Agnm2, autoimmune glomerulonephritis in MRL 2
Anxty, anxiety
Bmd7, bone mineral density 7
Dcdc5, doublecortin domain containing 5
Hyal4, hyaluronoglucosaminidase 4
Hyal5, hyaluronoglucosaminidase 5
Hyal6, hyaluronoglucosaminidase 6
Spam1, sperm adhesion molecule 1
Wasl, Wiskott-Aldrich syndrome-like (human)

11: 5864894-5891207
11: 5864894-5891207
8: 80875682-80881683
8: 80875682-80881683
13: 104665228-104684576
13: 104665228-104684576
13: 104701994-104824890
13: 104528844-104542789
8: 80947042-81014484
13:10435947-10438947
2: 106553007-106556649
2: 106553007-106556649
2: 106553007-106556649
2: 106553007-106556649
2: 106553007-106556649
8: 81034594-81058787
8: 81029162-81029320
1: 126683785-126717845
1: 126683785-126717845
6: 24951661-25113230
14: 58830212-58836142
14: 58830212-58836142
14: 58830212-58836142
14: 58830212-58836142
13: 117968579-117969103
9: 27911936-27975158
1: 171619669-171639814
1: 171619669-171639814
1: 171619669-171639814
1: 171619669-171639814
13: 105275519-105288870
6: 24067291-24276244
11: 6501551-6527323
11: 6501551-6527323
11: 6501551-6527323
11: 33621650-33649999
11: 33621650-33649999
9: 21242462-21309077
9: 21242462-21309077
13: 118500852-118528940
6: 140330684-140381709
4: 118439097-118439315
4: 118439097-118439315
4: 118439097-118439315
2: 106132643-106160544
6: 24597981-24886492
6: 24597981-24886492
6: 24597981-24886492
6: 24597981-24886492
6: 24597981-24886492

2.815092
2.815092
2.801206
2.801206
2.794302
2.794302
2.694254
2.686086
2.613413
2.499005
2.467799
2.467799
2.467799
2.467799
2.467799
2.46594
2.449382
2.332438
2.332438
2.312636
2.296665
2.296665
2.296665
2.296665
2.276845
2.215064
2.206376
2.206376
2.206376
2.206376
2.178497
2.158614
2.138303
2.138303
2.138303
2.110309
2.110309
2.106644
2.106644
2.106644
2.105794
2.097489
2.097489
2.097489
2.080386
2.051474
2.051474
2.051474
2.051474
2.051474
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Fhit, fragile histidine triad gene
Ctrq2, C. trachomatis resistance QTL 2
Dkk2, dickkopf homolog 2 (Xenopus laevis)
Dym, dymeclin
Idd21.1, insulin dependent diabetes susceptibility 21.1
Pgis1, proteoglycan induced spondylitis 1
Bmd4, bone mineral density 4
Mob5, multigenic obesity 5
Plast2b, plasma plant sterol 2b
T2dm2sa, type 2 diabetes mellitus 2 in SMXA RI mice
Tmc1m1, Tmc1 modifier 1
Dclre1a, DNA cross-link repair 1A, PSO2 homolog (S. cerevisiae)
Rpl21-ps4, ribosomal protein L21, pseudogene 4
Slit3, slit homolog 3 (Drosophila)
W6q3, weight 6 weeks QTL 3
Synpr, synaptoporin
Ptprg, protein tyrosine phosphatase, receptor type, G
Afap1l2, actin filament associated protein 1-like 2
Tdrd1, tudor domain containing 1
Vwa2, von Willebrand factor A domain containing 2
Lrrk2, leucine-rich repeat kinase 2
Slc2a13, solute carrier family 2 , member 13
Myo5b, myosin VB
Cadps, Ca2+-dependent secretion activator
Wdr67, WD repeat domain 67
Aod2, autoimmune ovarian dysgenesis 2
Ath13, atherosclerosis 13
Plast1, plasma plant sterol 1
Plast1b, plasma plant sterol 1b
Lrrc3b, leucine rich repeat containing 3B
Appd2, APP associated premature death 2
Nhlrc2, NHL repeat containing 2
n-R5s44, nuclear encoded rRNA 5S 44
Idd21.2, insulin dependent diabetes susceptibility 21.2
Gm3614, predicted gene 3614
Fezf2, Fez family zinc finger 2
Anxty, anxiety
Bmd7, bone mineral density 7
Ctrcts, cataract severity
Eae40, experimental allergic encephalomyelitis 40
Dcc, deleted in colorectal carcinoma
Dclre1a, DNA cross-link repair 1A, PSO2 homolog
Nek10, NIMA (never in mitosis gene a)- related kinase 10
Atrnl1, attractin like 1
Rthyd3, resistance to thymic deletion 3
Casp7, caspase 7
Bmd39, bone mineral density 39
F11, coagulation factor XI
Fat1, FAT tumor suppressor homolog 1 (Drosophila)
Mtnr1a, melatonin receptor 1A

14: 11584520-11656529
3: 131789521-131823292
3: 131789521-131823292
18: 75266222-75267209
18: 75266222-75267209
18: 75266222-75267209
15: 56618365-56626586
2: 110016970-110020628
2: 110016970-110020628
2: 110016970-110020628
2: 110016970-110020628
19: 56596851-56621288
14: 12042049-12162496
11: 35100995-35120899
11: 35100995-35120899
14: 14202231-14220929
14: 12445127-12526023
19: 56936971-56992931
19: 56936971-56992931
19: 56936971-56992931
15: 91386924-91588341
15: 91386924-91588341
18: 74863638-74889684
14: 13563270-13578052
15: 57796753-57816553
3: 52458253-52592669
14: 82146864-82154961
14: 82146864-82154961
14: 82146864-82154961
14: 16205186-16228725
14: 17434991-17580486
19: 56570749-56660884
14: 9779720-9874620
14: 14470385-14489374
14: 11969250-12401283
14: 13174979-13196712
4: 125536444-125587189
4: 125536444-125587189
4: 125536444-125587189
4: 125536444-125587189
18: 72369674-72489317
19: 56556474-56716524
14: 15737733-15748613
19: 58171868-58183830
14: 13316480-13423496
19: 56510580-56536292
8: 46044747-46343089
8: 46044747-46343089
8: 46044747-46343089
8: 46044747-46343089

2.94897
2.714458
2.714458
2.693152
2.693152
2.693152
2.660179
2.655399
2.655399
2.655399
2.655399
2.587244
2.564197
2.520235
2.520235
2.497986
2.492895
2.488735
2.488735
2.488735
2.478729
2.478729
2.473403
2.459644
2.381197
2.37429
2.346516
2.346516
2.346516
2.341599
2.290776
2.285557
2.281791
2.267598
2.257278
2.241588
2.205249
2.205249
2.205249
2.205249
2.200258
2.174883
2.151523
2.133273
2.132206
2.119476
2.108621
2.108621
2.108621
2.108621
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Fhit, fragile histidine triad gene
Ptprg, protein tyrosine phosphatase, receptor type, G
Slit3, slit homolog 3 (Drosophila)
W6q3, weight 6 weeks QTL 3
n-R5s44, nuclear encoded rRNA 5S 44
Synpr, synaptoporin
Cadps, Ca2+-dependent secretion activator
Dym, dymeclin
Idd21.1, insulin dependent diabetes susceptibility 21.1
Pgis1, proteoglycan induced spondylitis 1
Atxn7, ataxin 7
Prdt2, prion disease incubation time 2
Rpl21-ps4, ribosomal protein L21, pseudogene 4
Scgq3, spontaneous crescentic glomerulonephritis QTL 3
Spint4, serine protease inhibitor, Kunitz type 4
Wfdc10, WAP four-disulfide core domain 10
Wfdc11, WAP four-disulfide core domain 11
Wfdc13, WAP four-disulfide core domain 13
Wfdc9, WAP four-disulfide core domain 9
Rthyd3, resistance to thymic deletion 3
Tmc1m4, Tmc1 modifier 4
Fezf2, Fez family zinc finger 2
Thoc7, THO complex 7 homolog (Drosophila)
Bmd4, bone mineral density 4
Lrrc3b, leucine rich repeat containing 3B
Ity2a, immunity to S. typhimurium 2a
Ath13, atherosclerosis 13
Plast1, plasma plant sterol 1
Plast1b, plasma plant sterol 1b
Mob5, multigenic obesity 5
Plast2b, plasma plant sterol 2b
T2dm2sa, type 2 diabetes mellitus 2 in SMXA RI mice
Bglu1, blood glucose level 1
Wfdc16, WAP four-disulfide core domain 16
Wfdc6b, WAP four-disulfide core domain 6B
Wfdc8, WAP four-disulfide core domain 8
Olfr720, olfactory receptor 720
Alan2, alloantigen response 2
Athsq1, atherosclerosis susceptibility QTL 1
Bmd7, bone mineral density 7
Cinda3, cytokine induced activation 3
Fhad1, forkhead-associated (FHA) phosphopeptide binding domain
1
Lama1, laminin, alpha 1
Pregq4, pregnancy QTL 4
Psmd6, proteasome 26S subunit, non-ATPase, 6
Tbqt5, tibia bone quality traits 5
Appd2, APP associated premature death 2
Tmc1m1, Tmc1 modifier 1
Nek10, NIMA (never in mitosis gene a)- related kinase 10
Olfr31, olfactory receptor 31

14: 11584520-11656342
14: 12838623-12859093
11: 35100995-35120899
11: 35100995-35120899
14: 9797430-9881986
14: 14202231-14220929
14: 13452033-13505602
18: 75261748-75269685
18: 75261748-75269685
18: 75261748-75269685
14: 14797756-14919236
2: 178866494-178868269
14: 12042049-12079505
2: 164473694-164543019
2: 164473694-164543019
2: 164473694-164543019
2: 164473694-164543019
2: 164473694-164543019
2: 164473694-164543019
14: 13387864-13423496
5: 104462697-104463002
14: 13308624-12210361
14: 14772525-14930217
15: 56618365-56626586
14: 16208056-16246773
11: 52134589-52150216
14: 82146864-82154961
14: 82146864-82154961
14: 82146864-82154961
2: 110016970-110066102
2: 110016970-110066102
2: 110016970-110066102
2: 164422011-164543944
2: 164422011-164543944
2: 164422011-164543944
2: 164422011-164543944
14: 14996243-15046024
4: 141503560-141529979
4: 141503560-141529979
4: 141503560-141529979
4: 141503560-141529979
4: 141503560-141529979

2.790107
2.629132
2.622682
2.622682
2.509633
2.488148
2.469775
2.411058
2.411058
2.411058
2.400826
2.399079
2.389314
2.387713
2.387713
2.387713
2.387713
2.387713
2.387713
2.386053
2.382099
2.32838
2.314043
2.297213
2.285353
2.281033
2.278372
2.278372
2.278372
2.257479
2.257479
2.257479
2.250826
2.250826
2.250826
2.250826
2.24221
2.234897
2.234897
2.234897
2.234897
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17: 68051652-68076393
17: 68051652-68076393
14: 14725549-15046584
13: 107080581-107145390
14: 17565088-17626508
2: 110016289-110086903
14: 15683725-15694698
14: 15106114-15169235

2.234897
2.22981
2.22981
2.222066
2.205249
2.174883
2.166578
2.165838
2.14145
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Abstract
Background
Omega 3 (n-3) fatty acids (FAs) have been found to inhibit proliferation, induce
apoptosis, and promote differentiation in various cell types. The processes of cell
survival, expansion, and differentiation are of key importance in the regulation of
hematopoiesis. We investigated the role of n-3 FAs in controlling the frequency of
various myeloid progenitor cells in the bone marrow of mice. Increased progenitor cell
frequency and blocked differentiation are characteristics of hematopoietic disorders of the
myeloid lineage, such as myeloproliferative diseases and myeloid leukemias.
Results
We found that increasing the proportion of n-3 FAs relative to the proportion of
omega 6 (n-6) FAs in the diet caused increased differentiation and reduced the frequency
of myeloid progenitor cells in the bone marrow of mice. Furthermore, increasing the
proportion of n-3 FAs relative to the proportion of omega 6 (n-6) FAs in the diet had no
adverse effect on peripheral white blood cell counts.
Conclusion
Our results indicate that n-3 FAs impact hematopoietic differentiation by reducing
myeloid progenitor cell frequency in the bone marrow and promoting progenitor cell
differentiation. Further exploration of this discovery could lead to the use of n-3 FAs as a
therapeutic option for patients that have various disorders of hematopoiesis.
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Introduction
n-3 and n-6 FAs are essential FAs that must be obtained from dietary sources.
Recently, the ratio of n-3 to n-6 FAs consumed in the diet has been studied in relevance
to cardiac health [1], neurological health [2], and cancer prevention [1]. n-3 FAs can
compete with n-6 FAs for the same metabolic enzymes. n-3 and n-6 FAs are incorporated
into cell membranes either directly or after elongation and desaturation by Δ4, Δ5, and
Δ6 desaturases [3, 4]. n-3 FAs have greater affinity for the Δ4 and Δ6 desaturases than n6 FAs [5-7]. Dietary linoleic acid (18:2, n-6) is generally considered to be the major
source of tissue arachidonic acid (20:4, n-6) although meat fat can be a direct source of
arachidonic acid [8]. All three major n-3 FAs, α linolenic acid (18:3), eicosapentanoic
acid (20:5), and docosahexanoic acid (22:6), directly inhibit the production of
arachidonic acid from linoleic acid [5]. Both arachidonic acid and eicosapentanoic acid
can be cleaved from the cell membrane phospholipid stores by phospholipase A2 and
acted on by cyclooxygenases (either the constitutive COX1 or the inducible COX2) to
produce prostaglandin precursors that are isomerized by prostaglandin synthases to
produce prostaglandins. In this manner, COXs convert arachidonic acid to form the 2series prostaglandins that tend to be pro-proliferative and pro-inflammatory in most
tissues [9]. Micromolar concentrations of prostaglandin E2 (PGE2) increase human
myeloid progenitor cell proliferation [10]. However, COX activity on eicosapentanoic
acid forms the 3 series prostaglandins that tend to have anti-proliferative and antiinflammatory properties [9]. In addition to prostaglandins, leukotrienes and eicosanoids
are formed from FAs through the activity of various lipoxygenases. These have been
shown to have varying and sometimes controversial effects on either hematopoietic stem
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cell or myeloid progenitor cell differentiation [10, 11]. Thus, a model system approach is
needed to effectively dissect the net effect of dietary FAs on hematopoiesis in vivo.
Abnormal hematopoiesis often involves expansion of immature cells of the myeloid
lineage. In these cases, progenitor cell frequency could be expanded by increased
proliferation, decreased apoptosis, or both. If n-3 FAs inhibit proliferation or induce
apoptosis in myeloid progenitor cells, they could alleviate the cellular expansion that
occurs in certain disorders of hematopoiesis. Another characteristic of these disorders is a
block in differentiation. During normal hematopoiesis, a continuum of differentiation
exists, such that long term hematopoietic stem cells progressively differentiate to produce
terminally differentiated cells of the blood. Because n-3 FAs have been shown to promote
differentiation [10], they may serve as a therapeutic tool [12-15] for disorders involving
the inhibition of normal differentiation.
Our results indicate that the frequency of myeloid progenitors in the bone marrow
of mice fed fish oil diets is two-fold less than in those fed corn oil diets. Our data also
indicate that this reduction of progenitor cells does not have an adverse effect on the
number of circulating white blood cells in the periphery, even after prolonged dietary
change. These results suggest a possible role for n-3 FAs as therapeutic agents in
disorders involving expansion of myeloid progenitors, such as the myeloid leukemias.

Materials and methods
Animals
Mice used in this study were FVB X sv129F1 hybrid mice. FVB mice were of a
colony maintained by W. Elaine Hardman’s laboratory at Marshall University. They were
initially attained from Jeffrey E. Green’s laboratory (Lab of Cell Regulation and
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Carcinogenesis, National Cancer Institute, National Institute of Health, Bethesda, MD).
Sv129 mice were purchased from Charles River Laboratories (Wilmington, MA). Only
male mice were used to avoid cyclic changes in hormones. Mice were housed in the
AAALAC accredited animal facilities of the Marshall University School of Medicine. All
animal use and care was approved by the Marshall University Institutional Animal Care
and Use Committee. The mice were housed 3 to 4 in a cage and individually numbered
for identification.
Diet
The base diet was an American Institute of Nutrition (AIN)-76A diet modified by
substitution of 5% sucrose for 5% more oils to contain a total of 10% w/w oil (Tables 3.1
and 3.2). The fish oil diet contained 3.65% n-3 FAs and 1.3% n-6 FAs. The corn oil diet
contained 0.1% n-3 FAs and 6.1% n-6 FAs. Diets were prepared in the Marshall
University School of Medicine animal diet prep room. Diet composition is shown in
Table 3.1 and was formulated to be isocaloric, isonutrient and relevant to human
consumption. The AIN-76A diet is adequate for the nutritional support of the mice [28].
The dry ingredients of the diet were obtained in bulk from MP Biomedicals (Solon,
Ohio), sugar, corn and canola oil were purchased locally (100% canola oil, 100% corn
oil, no additives or preservatives). The n-3 supplement (OmegaRx Liquid) was purchased
from Zone Labs, Danvers, MA. Batches of diet were prepared as needed, about every two
weeks. The diet mixture was pressed into trays and cut into small squares. Individual
cage sized portions (25–30 g) were stored in sealed containers at -20°C to prevent
oxidation of the fat and bacterial growth in the food. Mice had free access to food and
water and were fed fresh food 5 days per week. Food removed from cages was discarded.
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Colony forming cell (CFC) assays
FVB X sv129 F1hybrid mice were fed either a fish oil diet (n = 5) or a corn oil
diet (n = 5) from weaning until 60 days old. CFC assays were then performed upon bone
marrow isolated from these mice as previously discussed [29, 30]. Briefly, bone marrow
was harvested by flushing from the femurs with Iscove's Modified Dulbecco's Medium
(IMDM) and cells were counted and seeded in 4 well plates at a density determined
empirically by a pilot study conducted with a broad and consistent range of seeding
densities. After linear response of colony production to seeding density was ensured by
the pilot study, seeding densities of 2.09 × 104 (fish oil) and 7.75 × 103 (corn oil)
cells/well were chosen to produce 10–30 colonies for each well. Bone marrow was
cultured in 1% semi-solid Methocult M3434 (StemCell Technologies), supplemented
with 0.4% autochthonous sera. Cells were incubated for 6–7 days to allow colony
formation. Colonies with a minimum cell number of 20 were scored as positive using an
inverted microscope at 40X magnification. Colonies were counted based on
morphological features that are associated with each progenitor type. Student's t type tests
were used to detect differences between the experimental groups (n = 5).

White blood cell counts
White blood cell counts were performed on EDTA anticoagulated peripheral
blood from tail veins of corn and fish oil fed female mice aged 115 days. Fish and corn
oil diets were instituted after weaning. Student's t type tests were used to detect
differences between the experimental groups.
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Results
High levels of n-3 FAs alter the character of the myeloid progenitor cell
compartment in the bone marrow
Progenitors for myeloid cells in bone marrow that can be assessed by CFC assays
include granulocyte erythrocyte macrophage megakaryocyte (GEMM) progenitors,
granulocyte macrophage (GM) progenitors, erythrocyte (E) progenitors, granulocyte (G)
progenitors, and macrophage (M) progenitors. Only these progenitors have the necessary
growth factors and proliferation capacity to produce colonies in the CFC assay.
Morphology of these colony types is shown in Figure 3.1. Mice were fed fish oil (high
level n-3 FAs) or corn oil (low level n-3 FAs) containing diets (Tables 3.1 and 3.2). Mice
that were fed the fish oil diet had a significantly lower (p = 0.010) frequency of total
myeloid progenitor cells (9.78 ± 0.46 × 10-4) than those mice fed the corn oil diet (2.10 ±
0.55 × 10-3) (Fig. 3.2A). These results indicate that n-3 FAs were inducing a reduction in
total myeloid progenitors in bone marrow. GM, G, and M progenitors were significantly
less (p < 0.05) frequent in the bone marrow of mice fed the fish oil diet than those fed the
corn oil diet (Fig. 3.2A). Interestingly, E progenitors did not change in their frequency
with diet, indicating n-3 FAs preferentially affected levels of GM progenitors and their
daughter cells (see Fig. 3.1). There was also an apparently larger frequency of GEMM
progenitors, which are early progenitors, in corn oil (5.16 ± 4.32 × 10-5) vs. fish oil (1.20
± 1.20 × 10-5) fed mice. Although this was a greater than 4 fold difference in frequency,
the difference was not statistically significant (p = 0.11) and the rarity of this progenitor
relative to others made it difficult to accurately assay with this technique.
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Analysis of the proportions of progenitor cells that make up the myeloid
progenitor cell compartment in these mice revealed that mice fed a fish oil diet had a
much different proportion of early and late stage progenitors compared to those fed a
corn oil diet (p = 0.00015). There was a greater percentage of later stage progenitor cells
(G, M, E progenitors) in fish oil diet fed mice (94.9 ± 1.6%) when compared to mice fed
a corn oil diet (71.3 ± 4.8%) (Fig. 3.2B). Conversely, there was a greater proportion of
earlier stage progenitors (GEMM and GM progenitors) in corn oil fed mice (28.7 ± 4.8%)
vs. fish oil fed mice (5.15 ± 1.6%). Thus, our data indicate that the bone marrow of mice
fed a high level of n-3 FAs had a more differentiated myeloid progenitor cell
compartment than that of mice fed a diet containing mostly n-6 FAs.
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Figure 3.1. Hematopoiesis differentiation continuum – myeloid progenitor
morphology. Hematopoiesis exists as a continuum of differentiation. Colony
morphology representing the various myeloid progenitor cells is shown (magnification =
100×) in a differentiation hierarchy beginning with the least differentiated progenitor and
continuing to the most differentiated progenitor. Abbreviations: Granulocyte erythrocyte
macrophage megakaryocyte (GEMM), granulocyte macrophage (GM), erythrocyte (E),
granulocyte (G), macrophage (M).
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Table 3.1: Modified AIN-76A Diet Composition.
Diet composition

% of
weight

Amount/100 g

Casein (protein)

20%

20 g

Sucrose

45%

45 g

Corn starch (carbs)

15%

15 g

Alphacel (fiber)

5%

5g

Choline bitartrate

0.2%

0.2 g

DL-methionine

0.3%

0.3 g

Mineral mix

3.5%

3.5 g

Vitamin mix

1.0%

1g

Fat

10%

10 g

Total

100%

100 g

Ingredient

Total fat

10 g

Total protein

20 g

Total carbohydrate

60 g

The base diet is an AIN-76A diet modified by substitution of 5% sucrose for 5% more oils to contain a
total of 10% w/w oil. The mouse food recipe contains 10% fat in each diet supplied through these oils.
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Table 3.2: Compositions of dietary fats (approximate %).
Saturated fatty
acids

Linoleic acid
(omega 6)

Total omega 3

Monounsaturated fatty
acids

Corn oila

13

61

1

26

Canola
oila

6

20

10

62

n-3 suppb

9

6

63

21

The corn oil diet is the low omega 3:omega 6 fatty acid diet containing 10% w/w corn oil as the source
of all fat. The fish oil diet is our high omega 3:omega 6 fatty acids diet containing 5% w/w canola oil
and 5% w/w omega 3 fatty acid supplement. The corn oil diet contains 0.1% omega 3 fatty acids and
6.1% omega 6 fatty acids, which is a relative ratio of omega 6 to omega 3 of 61: 1. The fish oil diet
contains 3.65% omega 3 fatty acids and 1.3% omega 6 fatty acids, which is a relative ratio of 1: 2.8.
a

From: http://www.nal.usda.gov/fnic/foodcomp/search

b

From: Manufacture's certified analyses.
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Figure 3.2: Fish oil diets cause changes in the steady state levels of myeloid
progenitors in the bone marrow. A. Colony forming cell (CFC) assay results of bone
marrow from mice fed corn oil (high n-6) vs. fish oil (high n-3) diets until 60 days of age.
Colonies formed represent the presence of a progenitor cell in which the type of colony
determines which progenitor cell type is present. Comparisons marked with (*) were
found to be significantly different (p < 0.05). Error bars represent SEMs (n = 5). B-C.
81

Data from A in which each colony type is shown as a proportion of total progenitor cell
frequency for each diet.

High levels of n-3 FAs do not have an adverse effect on white blood cell production
in the peripheral blood
To account for the concern that a lower progenitor cell frequency or a greater
proportion of differentiated progenitor cells in the bone marrow may cause a reduction in
white blood cells in peripheral blood and therefore a weakened immune system, we
performed white blood cell (WBC) counts on mice fed these diets from weaning to 115
days. Results indicated no significant differences in peripheral WBC counts between corn
oil fed mice (14,825 WBC/μl) and fish oil fed mice (13,760 WBC/μl) (Fig. 3.3). Thus,
fish oil diets induce a homeostatic condition of decreased progenitor cell frequency in the
myeloid compartment of the bone marrow without adverse effects on WBC production.
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Figure 3.3: Fish oil diets do not cause adverse reduction of white blood cell counts in
the peripheral blood. White blood cell (WBC) counts in WBC/μl from female mice on
the two diets until 115 days of age (n = 4 for fish oil, n = 5 for corn oil, p = 0.602). Error
bars represent SEMs.

Discussion
Our results indicate that n-3 FAs reduce total myeloid progenitor cell frequency
and promote differentiation of specific progenitor cell types in the bone marrow of mice.
Furthermore, this reduction of progenitors does not have an adverse effect on levels of
circulating white blood cells. Our data indicate that n-3 FA effects are particular to
granulocyte and macrophage progenitor cells rather than erythrocyte maturation. The
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effects of n-3 FAs may occur as early in maturation as the GEMM progenitor stage and
then be propagated to the GM and later progenitor stages. While our results indicate a
difference at the GM progenitor stage, they are also suggestive, although inconclusive, of
a difference at the GEMM stage. We are currently examining this question with ongoing
experiments to look at the earliest stem and progenitor cell stages of hematopoiesis.
Examination of the effects of n-3 FAs on hematopoiesis could lead to potential
therapeutic options for patients with disorders of the blood. Future work would include
investigating the mechanisms of action for these events. Mechanisms by which n-3 FAs
have been shown to inhibit proliferation, induce apoptosis, and promote differentiation in
many cancers include the regulation of signaling pathways and gene expression by
peroxisome proliferator receptor activator γ (PPARγ), for which n-3 FAs are natural
ligands [16]. Another mechanism of action of n-3 FAs includes inhibition of COX2,
which is upregulated in various cancers and is known to have proproliferative and
antiapoptotic effects [17-25]. Furthermore, the combination of activating PPARγ and
inhibition of COX2 expression has recently been shown to inhibit proliferation and
induce apoptosis in pancreatic cancer [26]. We plan to explore these, among other
mechanisms, using our animal model.
Regardless of the mechanisms by which n-3 FAs reduce and differentiate myeloid
progenitor cells in the bone marrow of mice, these dietary agents serve as a promising
option for therapy. The inhibitory effect of n-3 FAs on immune system function [10, 27]
has led to the use of fish oils that are high in these FAs in the management of several
inflammatory and autoimmune diseases [27]. Suppression of n-6 derived eicosanoids has
been proposed as a strategy for chemoprevention and as an adjunct for treatment of
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cancer [12-15]. Our results suggest that using n-3 FAs to more rapidly differentiate
myeloid progenitor cells may slow progression of disorders of hematopoiesis, including
leukemias, and restore a more normal myeloid progenitor cell compartment in the bone
marrow.

Competing interests
The authors declare that they have no competing interests.

Authors' contributions
MEV was responsible for the large part of data acquisition. MEV and VES
analyzed data and wrote this manuscript. WEH provided the mice with appropriate diets
and intellectual contributions on study design. VES and MEV provided intellectual
contribution on study design as well. VES coordinated the project.

Acknowledgments
This work was supported by NIH grants 1R03 CA129790, 1R01 CA114018, and
5P20RR020180 as well as with support from the NASA WV Space Grant Consortium
issued by NASA Goddard Space Flight Center, Grant Number NNG05GF80H. We
would like to acknowledge John Wilkinson IV for assistance in proofing the manuscript
and discussion of results as well as Yulia Dementieva for advisement on statistical
analysis.

85

References
1. Simopoulos, A.P., The importance of the ratio of omega-6/omega-3 essential fatty
acids. Biomed Pharmacother, 2002. 56(8):365-79.
2. Yehuda, S., Rabinovitz, S., Mostofsky, D.I., Essential fatty acids are mediators of brain
biochemistry and cognitive functions. J Neurosci Res, 1999. 56(6):565-70.
3. Emken, E., Adlof, R., Rakoff, H., Rohwedder, W., Metabolism of deuterium-labeled
linolenic, linoleic, oleic, stearic and palmitic acid in human subjects. In Synthesis and
applications of isotopically labelled compounds 1988. Edited by: Baillie T, Jones J.
Amsterdam: Elsevier Science Publishers, 1989:713-16.
4. Simopoulos, A.P., Omega-3 fatty acids in health and disease and in growth and
development. Am J Clin Nutr, 1991. 54(3):438-63.
5. Hagve, T., Christoffersen, B.O., Effect of dietary fats on arachidonic acid and
eicosapentaenoic acid biosynthesis and conversion to C22 fatty acids in isolated liver
cells. Biochim Biophys Acta, 1984. 796:205-17.
6. de Gomez Dumm, I.N., Brenner, R.R., Oxidative desaturation of alpha-linoleic,
linoleic, and stearic acids by human liver microsomes. Lipids, 1975. 10(6):315-17.
7. Hague, T., Christoffersen, B.O., Evidence for peroxisomal retroconversion of adrenic
acid (22:4n6) and docosahexanoic acid (22:6n3) in isolated liver cells. Biochim Biophys
Acta, 1986. 875:165-73.
8. Li, D., Ng, A., Mann, N.J., Sinclair, A.J., Contribution of meat fat to dietary
arachidonic acid. Lipids, 1998. 33(4):437-40.
9. Rose, D.P., Connolly, J.M., Omega-3 fatty acids as cancer chemopreventive agents.
Pharmacol Ther, 1999. 83(3):217-244.
10. Dupuis, F., Desplat, V., Praloran, V., Denizot, Y., Effects of lipidic mediators on the
growth of human myeloid and erythroid marrow progenitors. J Lipid Mediat Cell Signal,
1997. 16(3):117-25.
11. Rizzo, M.T., The role of arachidonic acid in normal and malignant hematopoiesis.
Prostaglandins Leukot Essent Fatty Acids, 2002. 66(1):57-69.
12. Germain, E., Lavandier F., Chajes, V., Schubnel V., Bonnet, P., Lhuillery, C.,
Bougnoux, P., Dietary n-3 polyunsaturated fatty acids and oxidants increase rat
mammary tumor sensitivity to epirubicin without change in cardiac toxicity. Lipids, 1999.
34(Suppl):S203.
13. Hardman, W.E., Barnes, C.J., Knight, C.W., Cameron, I.L., Effects of iron
supplementation and ET-18-OCH3 on MDA-MB 231 breast carcinomas in nude mice
consuming a fish oil diet. Br J Cancer, 1997. 76(3):347-54.
86

14. Karmali, R.A., Historical perspective and potential use of n-3 fatty acids in therapy of
cancer cachexia. Nutrition, 1996. 12(1 Suppl):S2-4.
15. Oberley, L.W., Spitz, D.R., Assay of superoxide dismutase activity in tumor tissue.
Methods Enzymol, 1984. 105:457-464.
16. Edwards, I.J., O'Flaherty, J.T., Omega-3 Fatty Acids and PPARgamma in Cancer.
PPAR Res, 2008. 2008:358052.
17. Higashi, Y., Kanekura, T., Kanzaki, T., Enhanced expression of cyclooxygenase
(COX)-2 in human skin epidermal cancer cells: evidence for growth suppression by
inhibiting COX-2 expression. Int J Cancer, 2000. 86(5):667-71.
18. Kondo, M., Yamamoto, H., Nagano, H., Okami, J., Ito, Y., Shimizu J., Eguchi, H.,
Miyamoto, A., Dono, K., Umeshita, K., et al., Increased expression of COX-2 in
nontumor liver tissue is associated with shorter disease-free survival in patients with
hepatocellular carcinoma. Clin Cancer Res, 1999. 5(12):4005-12.
19. Kulkarni, S., Rader J.S., Zhang, F., Liapis, H., Koki, A.T., Masferrer, J.L.,
Subbaramaiah, K., Dannenberg, A.J., Cyclooxygenase-2 is overexpressed in human
cervical cancer. Clin Cancer Res, 2001. 7(2):429-34.
20. Okami, J., Yamamoto, H., Fujiwara, Y., Tsujie, M., Kondo, M., Noura, S., Oshima,
S., Nagano, H., Dono, K., Umeshita, K., et al., Overexpression of cyclooxygenase-2 in
carcinoma of the pancreas. Clin Cancer Res, 1999. 5(8):2018-24.
21. Shamma, A., Yamamoto, H., Doki, Y., Okami, J., Kondo, M., Fujiwara, Y., Yano,
M., Inoue, M., Matsuura, N., Shiozaki, H., et al., Up-regulation of cyclooxygenase-2 in
squamous carcinogenesis of the esophagus. Clin Cancer Res, 2000. 6(4):1229-38.
22. Shirahama, T., Cyclooxygenase-2 expression is up-regulated in transitional cell
carcinoma and its preneoplastic lesions in the human urinary bladder. Clin Cancer Res,
2000. 6(6):2424-30. 24. Kargman, S.L., O'Neill, G.P., Vickers, P.J., Evans, J.F.,
23.Mancini, J.A., Jothy, S., Expression of prostaglandin G/H synthase-1 and -2 protein in
human colon cancer. Cancer Res, 1995. 55(12):2556-59.
24. Hwang, D., Scollard, D., Byrne, J., Levine, E., Expression of cyclooxygenase-1 and
cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst, 1998. 90(6):455-60.
25. Vecchini, A., Ceccarelli, V., Susta, F., Caligiana, P., Orvietani, P., Binaglia, L.,
Nocentini, G., Riccardi, C., Calviello, G., Palozza, P., et al., Dietary alpha-linolenic acid
reduces COX-2 expression and induces apoptosis of hepatoma cells. J Lipid Res, 2004.
45(2):308-16.
26. Sun, W.H., Chen G.S., Ou, X.L., Yang, Y., Luo, C., Zhang, Y., Shao, Y., Xu, H.C.,
Xiao, B., Xue, Y.P., et al., Inhibition of COX-2 and activation of peroxisome

87

proliferator-activated receptor gamma synergistically inhibits proliferation and induces
apoptosis of human pancreatic carcinoma cells. Cancer Lett, 2008. 275(2):247-55.
27. Kelley, D.S., Modulation of human immune and inflammatory responses by dietary
fatty acids. Nutrition, 2001. 17(7–8):669-73.
28. Report of the American Institute of Nutrition ad hoc committee on standards for
nutritional studies J Nutr, 1977. 107(7):1340-48.
29. Sollars, V.E., Pequignot, E., Rothstein, J.L., Buchberg, A.M., Analysis of expansion
of myeloid progenitors in mice to identify leukemic susceptibility genes. Mamm Genome,
2006. 17(8):808-21.
30. Miller, C.L., Lai, B., Human and Mouse Hematopoietic Colony-Forming Cell Assays.
In Basic Cell Culture Protocols, Volume 290. 3rd edition. Edited by: Helgason CD,
Miller CL. Totowa, NJ: Humana Press Inc; 2005:71-90.

88

Chapter 4: A high omega-3 fatty acid diet has different effects on
early and late stage myeloid progenitors
Melinda E. Varney1, James T. Buchanan1, Yulia Dementieva2, W. Elaine Hardman1, and
Vincent E. Sollars1,*
1

Department of Biochemistry and Microbiology, Marshall University School of

Medicine, One
John Marshall Drive, Huntington, WV 25755
2

Department of Mathematics, Marshall University, One John Marshall Drive,

Huntington, WV
25755
*Corresponding author
Department of Biochemistry and Microbiology
Joan C. Edwards School of Medicine, Marshall University School of Medicine
One John Marshall Drive, Huntington, WV 25755 USA
Tel: 304.696.7357
Fax: 304.696.7207
Email: sollars@marshall.edu
Lipids [In Press]

89

Abstract
The effects of the polyunsaturated omega-3 (n-3) and omega-6 (n-6) fatty acids
(FAs) on hematopoiesis are complex in that both FA forms are processed into
leukotrienes, eicosanoids, and prostaglandins, which can have independent effects. These
FAs have antagonistic effects in that n-6 FA prostaglandins tend to be pro-proliferative
and pro-inflammatory, whereas the effects of n-3 FA prostaglandins are the opposite. We
have previously shown that diets high in n-3 FAs reduce the size of the middle to later
stage myeloid progenitor compartment in FVB X sv129 F1hybrid mice. To assay the
effects of high n-3 FA diets on earlier stages of myelopoiesis, we fed C57BL/6J mice
diets high in n-3 FAs or at levels of n-3:n-6 FAs similar to western diets and assayed the
effects on myelopoiesis with flow cytometry and colony forming cell (CFC) assays.
Results indicate an expansion of the common myeloid progenitor cell compartment in
high n-3 FA diets, which does not persist into later stages where the number of progenitor
cells is actually lower in high n-3 FA fed animals. Investigations in vitro with the
hematopoietic stem cell line EML-clone 1 indicate that cells cultured with
eicosapentanoic acid (n-3 FA) or arachidonic acid (n-6 FA) have no differences in cell
viability but that arachidonic acid more rapidly produces progenitors with low levels of
the macrophage developmental marker, F4/80.

Key words: Omega fatty acids, EPA, DHA, immunology, stem cells, progenitor cells,
bone marrow, nutrition
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Introduction
The examination of omega-3 (n-3) and omega-6 (n-6) fatty acids (FAs) effects on
hematopoiesis is important to patient care. The inhibitory effect of n-3 FAs on
inflammation has led to the use of fish oils that are high in these FAs in the management
of several inflammatory and autoimmune diseases [1]. n-3 FAs affect hematopoietic
differentiation by influencing myeloid progenitor cells [2]. n-3 FAs are known to affect
immune system function by reducing several aspects of neutrophil, monocyte, and
lymphocyte function [1]. Suppression of n-6 derived eicosanoids has been proposed as a
strategy for chemoprevention and as an adjunct for treatment of cancer [3-6].
n-3 and n-6 FAs are incorporated into cell membranes either directly or after
elongation and then desaturation by 6 and 5 desaturases. Dietary linoleic acid (LNA,
18 carbons, n-6 FA) is generally considered to be the major source of tissue arachidonic
acid (ARA, 20 carbons, n-6 FA) although meat fat can be a direct source of ARA [7]. n-3
FAs have greater affinity for the 5 and 6 desaturases than n-6 FAs. Consequently,
increasing dietary intake of n-3 FAs reduces the desaturation of LNA and reduces the
production of ARA [8]. All three major n-3 FAs – α linolenic acid (ALA, 18:3, n-3),
eicosapentanoic acid (EPA, 20:5, n-3), and docosahexanoic acid (DHA, 22:6, n-3) –
directly inhibit the production of ARA from LNA [8].
Both ARA and EPA can be cleaved from the cell membrane phospholipids stores
by phospholipase A2 and acted on by cyclooxygenases (either the constitutive COX1 or
the inducible COX2) to produce prostaglandin precursors which are isomerized by
prostaglandin synthases to produce prostaglandins. COX activity on ARA forms the 2series prostaglandins that tend to be pro-proliferative and pro-inflammatory in most
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tissues [9]. Micromolar concentrations of prostaglandin E2 increase human myeloid
progenitor cell proliferation [2]. However, COX activity on EPA forms the 3 series
prostaglandins that tend to have anti-proliferative and anti-inflammatory properties [9]. In
addition to prostaglandins, leukotrienes and eicosanoids are formed from FAs through
activity of various lipoxygenases. These have been shown to have varying and sometimes
controversial effects on either hematopoietic stem cell or myeloid progenitor cell
differentiation [2, 10]. A model system approach is needed to effectively dissect the net
effect of dietary FAs on hematopoiesis in vivo.
In this study, we examined the effects of n-3 and n-6 FAs in vivo in the mouse,
with an analysis at the level of stem and progenitor subtypes. Our results indicate that,
compared to diets rich in n-6 FAs, diets rich in n-3 FAs induce lower levels of later stage
myeloid progenitor cells in mice but that there is a higher frequency of the earliest stage
myeloid progenitor cells in these mice. Our in vitro results indicate that aspects of the in
vivo effects of n-3 and n-6 FAs can be modeled using the EML cell culture system to
ascertain the mechanisms involved.

Materials and methods
Animals
C57BL/6J mice used in this study were purchased from The Jackson Laboratory
(Bar Harbor, ME). Only male mice were used to avoid cyclic changes in hormones. Mice
were housed in the AAALAC accredited animal facilities of the Marshall University
School of Medicine. All animal use and care was approved by the Marshall University
Institutional Animal Care and Use Committee. The mice were housed 3 to 4 in a cage and
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individually numbered for identification. Mice were fed either a fish oil diet (n=8) or a
corn oil diet (n=8) from 6 weeks of age until 20 wks of age (100 days on diet).

Diet
The base diet was an American Institute of Nutrition (AIN)-76A diet modified by
substitution of 5% sucrose for 5% more oils to contain a total of 10% w/w oil (Tables 4.1
and 4.2). The fish oil diet contained 3.65% n-3 FAs and 1.3% n-6 FAs. The corn oil diet
contained 0.1% n-3 FAs and 6.1% n-6 FAs. Diets were prepared in the Marshall
University School of Medicine animal diet prep room. Diet composition is shown in
Table 4.1 and was formulated to be isocaloric, isonutrient and relevant to human
consumption. The AIN-76A diet is adequate for the nutritional support of the mice [11].
The dry ingredients of the diet were obtained in bulk from MP Biomedicals (Solon,
Ohio): sugar, corn and canola oil were purchased locally (100% canola oil, 100% corn
oil, no additives or preservatives). The n-3 supplement (OmegaRx Liquid) was purchased
from Zone Labs, Danvers, MA. Batches of diet were prepared as needed, about every two
weeks. The diet mixture was pressed into trays. Food (25-30 g) was stored in sealed
containers at -20°C to prevent oxidation of the fat and bacterial growth in the food. Mice
had free access to food and water and were fed fresh food 5 days per week. Food
removed from cages was discarded.

Colony forming cell (CFC) assays
CFC assays were performed upon bone marrow isolated from C57BL/6 mice as
previously discussed [12, 13]. Briefly, bone marrow was harvested by flushing from the
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femurs with Iscove’s modified Dulbecco’s medium and cells were counted and seeded in
4 well plates in at a density determined empirically by a pilot study conducted with a
broad and consistent range of seeding densities. After linear response of colony
production to seeding density was ensured by the pilot study, seeding densities were
chosen to produce 10-30 colonies for each well (4-well plates). Bone marrow was
cultured in 1% semi-solid Methocult M3434 (StemCell Technologies) supplemented with
0.4% autochthonous sera. Cells were incubated for 6-7 days to allow colony formation.
Colonies with a minimum cell number of 20 were scored as positive using an inverted
microscope at 40X magnification. Colonies were counted based on morphological
features that are associated with each progenitor type.

Flow cytometry
The preparation of bone marrow for flow cytometry was performed as previously
described [12]. Erythroid myeloid lymphoid (EML) cells were prepared by washing twice
with FACS buffer (PBS supplemented with 0.5% bovine serum albumin and 2mM
EDTA) and collecting by centrifugation. Thereafter, samples were incubated with 2%
autochthonous sera obtained from cardiac puncture just before marrow harvest to prevent
nonspecific binding by blocking the Fc receptors for 30 minutes at 4°C. The cells were
washed again and labeled with antibodies for 30 minutes on ice. The following antibodies
were used in the bone marrow studies with Streptavidin-Pacific Blue to detect
biotinylated antibodies: PE-Cy7 conjugated Sca-1 (clone D7, eBiosciences #25-5981-81),
APC-eFluor 750 conjugated CD117 (clone 2B8, eBiosciences #47-1171-80), biotinylated
lineage panel (BD Biosciences #559971), biotinylated IL-7Rα (clone B12-1, BD
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Biosciences #555288), APC conjugated FCRγ (clone 93, eBiosciences #17-0161-81), and
PE conjugated CD34 (clone RAM34, BD Biosciences 551387). The following antibodies
were used in labeling the EML-clone1 cells in labeling pairs with Streptavidin-APC (BD
Biosciences #554067) to detect biotinylated antibodies: biotinylated Ly6G/C (clone RB68CS, BD Biosciences #553125) + PE conjugated CD117 (clone 2B8, BD Biosciences
#553355), biotinylated CD11b (clone M1/70, BD Biosciences #553309) + PE conjugated
Sca-1 (clone D7, BD Biosciences #553108), and biotinylated CD45 (clone RA3-6B2, BD
Biosciences #553086) + PE conjugated F4/80 (clone BM8, Caltag #MF48004). Data
acquisition was performed using BD FACS Aria I sorter and data analysis and
compensation was performed using FlowJo v. 7.6 software (Treestar, Ashland, OR) with
super-enhanced Dmax subtraction analysis for determination of small differences in
overlapping histograms. Algorithms for super-enhanced Dmax analysis are used to
calculate the percentage of positive cells found in the sample and not the control by
allowing for a quantitative subtraction of non-specific fluorescence.

In vitro culture and differentiation
EML C1 cells were the kind gift of Dr. Schickwann Tsai (University of Utah, Salt
Lake City, UT) and were maintained in Iscove’s modified Dulbecco medium (IMDM,)
supplemented with 20% horse serum (American Type culture collection, ATCC,
Manassas, VA) and 10% baby hamster kidney (BHK)/MKL cell conditioned medium
[14]. For differentiation studies, EML cells were induced to differentiate into myeloid
cells with 10μM all-trans retinoic acid (ATRA; Sigma, St. Louis, MO, USA), 10% BHK
cell conditioned medium (source of stem cell factor) and 15% WEHI (monocyte cell line)
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cell conditioned medium (source of interleukin-3) for three days. EML-clone1 cells
were seeded at 2x105 cells/mL and cultured for 24 hours in 60μM FAs in standard growth
medium (20% horse serum, 70% Dulbecco’s modified eagle medium, and 10% BHK cell
conditioned medium). After 24 hours cells were placed in differentiation medium with
60μM FAs at 2.0x105 cells/mL. Cell counts were performed using trypan blue at 24, 48,
72, and 96 hours. After 96 hours cells were processed for flow cytometry analysis.

Fatty acid metabolism studies
Cells were seeded at 2x105 cells/mL and treated with vehicle control of ethanol or
60μM FAs. The ethanol vehicle control was added in the same concentrations as FAs.
Cell counts were performed at 24, 48, 72, and 96 hours using trypan blue. At each time
point, half the total volume of the culture was taken as a sample and replaced with
untreated growth media. Each sample was centrifuged (500xg), the supernatant removed,
and the pellet stored at -20°C until analyzed by gas chromatography. At the time of gas
chromatography, cells were homogenized in 0.1% butylated hydroxytoluene in 70%
methanol/distilled water to prevent FA oxidation. Lipids were extracted with
chloroform/methanol and methylated. Methylated lipids were separated and identified
using gas chromatography as previously published [15]. FA methyl ester standards (NuChek-Prep, Elysian, MN) were used for peak identification. The FA methyl esters were
reported as the percent of the total methylated FAs (area under the curve).
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Statistical analysis
Statistical analyses were run using SAS software release 9.2 (SAS Institute Inc.
Cary, NC). Student’s t-tests were used to detect differences between the experimental
groups (corn oil versus fish oil diet) of colony forming cells (n=8 for each group) and
between the experimental groups (corn oil versus fish oil diet) in flow cytometry assays
(n = 8 for each group). To determine statistical significance in gas chromatography
experiments and differentiation studies the levels of FAs of a particular type were
analyzed using either one-way analysis of variance (ANOVA) or by one-way KruskalWallis analysis of variance on ranks. Dunnett multiple comparison tests were used for
testing if any treatments are significantly different from a single control for all main
effects means in the MEANS statement.

Results
Fish oil diets induce changes in the frequency of various myeloid progenitor cell
types in the bone marrow
In our previous investigations of the effect of fish oil diets on murine
hematopoiesis, we found a down-regulation in the frequency of myeloid progenitor cells
in bone marrow in mice fed fish oil diets compared to those on corn oil diets[16]. Other
investigators have reported that bone marrow of rodents readily changes composition
based upon dietary FA sources [17]. However, our investigations using CFC assays
limited our ability to assay the frequency of more immature cell types, such as the
common myeloid progenitor (CMP, same as GEMM) and hematopoietic stem cell
(HSC). In order to assay the effects of high n-3 FA diets on these cell types, we verified
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that the effects seen in FVB X sv129 F1 hybrid animals were also seen in C57BL/6 mice
in which flow cytometry markers for examining these rare cell types have been verified
[18]. In the experiments presented here, mice were fed diets rich in n-3 FAs (fish oil diet)
or rich in n-6 FAs (corn oil diet) from 6 weeks of age until 20 wks of age (Tables 4.1 and
4.2, 100 days on diet). Bone marrow was then harvested and analyzed by colony forming
cell assay and flow cytometry. There was no difference in density of cells in the bone
marrow (Fig. 4.1A). Our results (Fig. 4.1B) indicated an overall lower frequency of mid
to late stage progenitors when mice were fed n-3 FA rich diets compared to those that
were fed n-6 FA rich diets. There was a significantly lower (26%, p-value < 0.01) overall
myeloid progenitor cell frequency, with significant reductions (p-value < 0.05) in colony
forming unit granulocyte-macrophage (CFU-GM) and colony forming unit macrophage
(CFU-M).
When we examined the relative contributions of each progenitor cell type to the
overall myeloid progenitor cell pool in the bone marrow (Fig. 4.1C), we found that there
is a significant reduction in CFU-GM proportion in mice on the fish oil diet (p-value <
0.05). The comparison of proportions of subtypes of myeloid progenitors is different
from what we observed in FVB X sv129 F1 hybrid mice [16], where we observed an
overall shift to more later stage progenitor types [16]. Thus, though there was a reduction
in myeloid progenitor cell frequencies in the marrow and a two-fold reduction in
proportion of CFU-GM, there was little shift in proportions of the other progenitor
subtypes. This difference may be due to particular characteristics of the C57BL/6 inbred
strain that are not seen in F1 hybrid animals, possibly including the lessening of
homozygous recessive mutations in hybrid animals. In a previous publication, we have

98

shown that mice vary significantly in myeloid progenitor cell frequencies [12]. These
data indicate that C57BL/6 mice responded to high n-3 FA diets with a reduction in
overall myeloid progenitor cell frequencies and significantly altering the proportions of
the CFU-GM present.

Table 4.1: Modified AIN-76A Diet Composition.
Diet composition
% of
weight

Amount/100 g

Casein (protein)

20%

20 g

Sucrose

45%

45 g

Corn starch (carbs)

15%

15 g

Alphacel (fiber)

5%

5g

Choline bitartrate

0.2%

0.2 g

DL-methionine

0.3%

0.3 g

Mineral mix

3.5%

3.5 g

Vitamin mix

1.0%

1g

Fat

10%

10 g

Total

100%

100 g

Ingredient

Total fat

10 g

Total protein

20 g

Total carbohydrate

60 g

The base diet is an AIN-76A diet modified by substitution of 5% sucrose for 5% more oils to
contain a total of 10% w/w oil. The mouse food recipe contains 10% fat in each diet supplied
through these oils.
99

Table 4.2: Compositions of dietary fats (approximate %).
Saturated fatty
acids

Linoleic acid
(omega 6)

Total omega 3

Monounsaturated fatty
acids

Corn oila

13

61

1

26

Canola
oila

6

20

10

62

n-3 supp.b

9

6

63

21

The corn oil diet is the low omega 3:omega 6 fatty acid diet containing 10% w/w corn oil as the
source of all fat. The fish oil diet is our high omega 3:omega 6 fatty acids diet containing 5% w/w
canola oil and 5% w/w omega 3 fatty acid supplement. The corn oil diet contains 0.1% omega 3 fatty
acids and 6.1% omega 6 fatty acids, which is a relative ratio of omega 6 to omega 3 of 61: 1. The fish
oil diet contains 3.65% omega 3 fatty acids and 1.3% omega 6 fatty acids, which is a relative ratio of
1: 2.8.
a

From: http://www.nal.usda.gov/fnic/foodcomp/search

b

From: Manufacture's certified analyses.
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Figure 4.1: Reduction in middle to latter stage myeloid progenitor cell types by high
n-3 diet. Mice were fed either corn oil or fish oil diets for 100 days followed by
harvesting of bone marrow from femurs. A. The number of cells harvested from the mice
on the different diets was similar. B. Colony forming cell assays were performed to
enumerate the frequency of middle to latter stage progenitor types. The frequency of each
progenitor cell type is shown. C. The relative distribution of progenitor types in the total
progenitors assayed is shown. Significant differences as measured by Student’s t-tests (pvalue < 0.05) are indicated by *. Error bars represent SEM (n=8). SEMs in (C) for the
corn oil diet data are BFU-E: 2.4%, CFU-GEMM: 0.8%, CFU-GM: 1.1%, CFU-G: 2.7%,
CFU-M: 1.8% and for the fish oil diet are BFU-E: 2.4%, CFU-GEMM: 0.6%, CFU-GM:
0.5%, CFU-G: 2.1%, CFU-M: 2.1%. Abbreviations are: colony forming unit (CFU), blast
forming unit (BFU), granulocyte erythrocyte monocyte macrophage (GEMM),
erythrocyte (E), granulocyte monocyte (GM), granulocyte (G), and macrophage (M).
101

The frequency of the common myeloid progenitor fraction is increased in mice fed
fish oil diets
In order to assay the frequencies of earlier stage stem and progenitors cells in
mice fed corn and fish oil diets, flow cytometry studies were conducted using established
gating parameters from the Weissman lab [18] for the assay of HSCs, CMPs,
granulocyte-macrophage progenitors (GMPs), and megakaryocyte-erythrocyte
progenitors (MEPs) in C57BL/6 mice (Fig. 4.2A). Bone marrow cells were first gated by
excluding high and low forward scatter cells along with those labeled positively for one
of the differentiation antigens (refer to Table 4.3) in the lineage panel or IL-7Rα, which
marks lymphoid cells. This population of FSCmidIL-7Rα–Lin– cells was further gated into
stem (FSCmidIL-7Rα–Lin–Sca-1+c-Kit+) and progenitor (FSCmidIL-7Rα–Lin–Sca-1–c-Kit+)
cell fractions by expression of c-Kit and Sca-1 as shown. The progenitor pool was also
analyzed and gated based upon the expression of CD34 and FcγR to delineate CMPs
(FSCmidIL-7Rα–Lin–Sca-1+c-Kit+FcγRloCD34+), GMPs (FSCmidIL-7Rα–Lin–Sca-1+cKit+FcγRhiCD34+), and MEPs (FSCmidIL-7Rα–Lin–Sca-1+c-Kit+FcγRloCD34–). These
data show a 50% increase (p-value = 0.01) in the frequency of the CMP fraction in mice
fed fish oil diets (Fig. 4.2B). There were no significant differences in frequency of HSC,
GMP, or MEP fractions indicated in these studies. These data suggest that the frequency
of the CMP has been increased by administration of a diet containing high levels of n-3
FAs.
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Table 4.3: Flow cytometry markers for gating populations of stem and early
myeloid progenitor cells.
Flow Cytometry Marker
Lineage panel
IL-7Ra
Sca-1
C-kit
FcR
CD34

Cell Population Positive for Marker
Differentiated cells
Lymphocyte progenitors
Stem cells
Stem and progenitor cells
MEPs and CMPs - low positive
GMPs - high positive
GMPs and CMPs

Figure 4.2: Increase in early myeloid progenitors by high n-3 diets. Mice were fed
either corn oil or fish oil diets for 100 days followed by harvesting of bone marrow
from femurs. A. Representative plots are displayed to show gating parameters. Bone
marrow cells were analyzed by flow cytometry first by FSC X lineage panel + IL7Rα
(left panel). R1 represents the population of undifferentiated cells of the myeloid lineage.
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This population was further analyzed by C-kit and Sca-1 expression, allowing for the
gating of the HSC and R2 populations. R2 represents early progenitor cell populations.
The R2 population was further analyzed and gated into CMP, GMP, and MEP
populations based on FcγR X CD34 expression. B. The percentage of the total marrow
cells labeling positive for each fraction are shown. Significant differences as measured by
Student’s t-tests (p-value <0.05) are indicated by *. Error bars represent SEM (n=8).
Abbreviations are: hematopoietic stem cells (HSCs), common myeloid progenitors
(CMPs), granulocyte macrophage progenitors (GMPs), and megakaryocyte erythrocyte
progenitors (MEPs).

FAs applied to EML cell culture medium are incorporated and processed
In order to study the observed effects of n-3 vs. n-6 FAs on early myeloid
progenitor cells in more detail, we examined the effects of the polyunsaturated FAs EPA
and ARA on EML cells in culture. We chose to compare these two FAs because EPA
(20:5, n-3) is the FAs most molecularly similar to ARA (20 carbons, n-6 FA) available.
DHA (22:6, n-3) has two more carbons in the chain. The EML cell line is a stem cell
factor dependent multipotent cell line with erythroid (E), myeloid (M), and lymphoid (L)
potential. It was established from DBA/2 mouse bone marrow infected with a retroviral
vector (LRARα403SN) harboring a dominant negative retinoic acid receptor [14]. It is a
suspension cell line consisting of mostly blast like cells with 20-30% hand mirror shaped
cells. EML cells serve as an excellent model to study hematopoietic differentiation. It can
be induced to differentiate toward granulocyte/monocyte progenitors by high
concentration of all-trans retinoic acid (ATRA) in the presence of interleukin-3 (IL-3).
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To verify the incorporation and processing by EML cells of FAs placed in the
culture medium, we spiked the culture medium with 60μM ARA (Fig. 4.3A) or 60μM
EPA (Fig. 4.3B) and analyzed the levels of various FAs present in the cells over the
course of four days. Cells were analyzed with gas chromatography daily to determine the
uptake and processing of FAs. The major FAs in untreated EML cell membranes are
steric acid, oleic acid, LNA, and ARA (time 0). There are only faint traces of n-3 FAs
such as ALA, EPA, docosapentanoic acid (DPA), and DHA in EML cell membranes
under normal culturing conditions (time 0). In both cultures, the percentage of the major
constituent of cell membranes (steric acid) is reduced as this is replaced by either ARA or
EPA (Figs. 4.3A and 4.3B, 24 hours). Thus, FAs supplied in culture medium were being
incorporated into cellular membranes and this occurs within 24 hours. Supplementation
of ARA in the medium caused an increase in the already substantial levels of ARA in
cellular membranes (Fig. 4.3A). There was a significant (p-value < 0.05) two-fold
increase in ARA at 24 hours that drops to a 66% increase at 48 hours and was maintained
for the remainder of the 4 days. The addition of EPA to the culture medium caused a
significant (p-value < 0.001) increase in the n-3 FA EPA and elevated levels (p-value
significant before correction for multiple comparisons) of the EPA elongation metabolite
DPA, with a corresponding significant (p-value < 0.001) decrease in ARA by 24 hours
(Fig. 4.3B). Interestingly, there was no increase in DHA, which is the 4 desaturase
metabolite of DPA, indicating EML cells do not have this enzymatic activity. Thus,
addition of FAs to the cell medium resulted in incorporation of FAs into cellular
membranes and processing by 24 hours.
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Figure 4.3: EML cells take up and metabolize FAs. EML cells were placed in growth
medium containing 60μM arachidonic (A) or eicosapentanoic (B) acid. The uptake and
processing of these FAs was assayed over the course of four days. Samples were taken
just before addition of the FAs (t = 0), 24 hours, 48 hours, 72 hours, and 96 hours for
analysis by gas chromatography. The gas chromatography data for each FA is shown
above for the five data points in temporal order. Data displayed are the results of three
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independent experiments with the mean and SEM displayed. Abbreviations: linoleic acid
(LNA), alpha-linolenic acid (ALA), arachidonic acid (ARA), eicosapentanoic acid
(EPA), docosapentanoic acid (DPA), and docosahexanoic acid (DHA). (*) indicate
statistically significant (p-value < 0.05) differences based on one-way ANOVA test or
Kruskal-Wallis test with Dunnett multiple comparisons adjustment. (**) indicate
statistically significant (p-value < 0.05) differences based on Student’s t-test or MannWhitney rank sum test without multiple comparison adjustment.

Incubation of EML cells with FAs has effects on immunophenotype and cell
proliferation
To determine if the effects of n-3 vs. n-6 FAs seen in our in vivo experiment are
due to viability or proliferation differences induced by the FAs, we analyzed the effect of
n-3 and n-6 FAs on EML cells in culture (Fig 4.4A) for two days, as we have shown that
the greatest levels of incorporation of FAs supplied through the culture medium occur at
24 hours according to the gas chromatography. EML cells in their native state are a
model for hematopoietic stem cells. We found that cultures treated with 60μM ARA had
significantly reduced (p-value < 0.05) cell counts after one day compared to the vehicle
control. EPA treated cultures had slightly lower cell counts at day one, but the difference
was not statistically significant. Neither of the treated cultures had statistically significant
differences from the control at day 2, indicating that the effects of treatment with ARA
were transitory. These results are consistent with the in vivo results, in which we saw no
difference in the stem cell compartment of fish oil (high n-3) vs. corn oil (high n-6) fed
mice.
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To observe cell autonomous effects of n-3 vs. n-6 FAs on cell viability and
proliferation during GMP myeloid progenitor cell differentiation, we primed EML cells
for 24 hours with 60μM EPA or ARA and then induced differentiation into
macrophage/granulocytic lineages with ATRA, stem cell factor (SCF), and IL-3. After
24, 48, and 72 hours in the differentiation medium, cell counts were performed on these
EML cell cultures. Viability was measured by trypan blue dye exclusion (Fig. 4.4B). The
viability of the cell cultures was very similar with the various treatments at each stage
with a fairly consistent viability as the cultures differentiated (measured by non-stained
cells/total cells, data not presented). There were no differences in viability when a oneway ANOVA tests were run. All cultures were proliferating robustly with a doubling
time starting at 18 hours and shortening as differentiation proceeded (data not presented).
The major finding of this study was a significant reduction compared to control (p-value
< 0.05) in cell counts in the EPA treatment group at days 2 (11% reduction) and 3 (21%
reduction) with a suggestive reduction at day 1 (Fig. 4.4B). No reduction in viability of
the cultures at these time points suggests that the difference was due to cell proliferation.
These results are consistent with our in vivo results that show a higher frequency of
middle-later stage myeloid progenitors with high n-6 diets.
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Figure 4.4: In vitro culture of EML cells shows differences in cell proliferation
between n-3 vs. n-6 treated cultures. A. EML cells in standard culture were treated with
either vehicle control, arachidonic acid (n-6), or eicosapentanoic acid (n-3) for 48 hours
with cell counts performed at 24 and 48 hours. B. EML cells were cultured in either
vehicle control, arachidonic acid (n-6), or eicosapentanoic acid (n-3) for 24 hours then
induced to differentiate for another 72 hours down myeloid lineages. Data displayed are
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the results of two (A) or three (B) independent experiments with the mean and SEM
displayed of culture counts normalized to the vehicle control. (*) indicate statistically
significant (p-value < 0.05) difference based on one-way ANOVA test with Dunnett
multiple comparisons adjustment.

To observe cell autonomous effects of n-3 vs. n-6 FAs on myeloid progenitor cell
differentiation we primed EML cells for 24 hours with 60μM EPA or ARA and then
induced differentiation into macrophage/granulocytic lineages with ATRA, SCF, and IL3. After 72 hours in the differentiation medium, EML cells were immunophenotyped for
the early markers (refer to Table 4.4) Sca-1 and CD117, as well as the differentiation
markers Ly6G, CD11b, CD45, and F4/80 (Fig. 4.5B). There were no significant
decreases in Sca-1 levels (the first sign of differentiation in this model) with treatment,
though the decrease with ARA treatment is suggestive (p-value significant before
correction for multiple comparisons, but not after the appropriate Dunnett multiple
comparison correction) when comparing treatments to vehicle control. There was a
significant (p-value < 0.05) difference in the percentage of cells labeling with the F4/80
antigen in the ARA treatment group compared to the vehicle control. The sizeable
increase in F4/80 positive cells coupled with the suggestive decrease for the Sca-1
antigen in the treatments with ARA compared to vehicle (Fig. 4.5B) indicates the
production of a granulocyte/macrophage progenitor population with ARA treatment.
These two results are consistent in that there is a lower frequency of the marker for stem
cells and an increase in frequency of the differentiation marker F4/80. This result is also
consistent with the in vivo data that found an increase in production of macrophage
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progenitor subtypes at a later stage in the differentiation continuum of hematopoiesis
(Fig.4.1B). The expression of F4/80 appears to be at a low abundance on a per cell basis
in both ARA and EPA treated samples but much more prevalent in ARA treated samples
(Fig. 4.5C). Thus, our model suggests that the differences in the common myeloid
progenitor compartment in our in vivo experiment are not due to changes in rate of
differentiation in the bone marrow and that n-6 FA supplementation produces a shift to
macrophage/granulocytic lineages as seen in vivo.

Table 4.4: Flow cytometry markers for gating populations at various stages in the
differentiation continuum
Flow Cytometry Marker
Sca-1
C-kit (CD117)
F4/80
Ly6G
CD11b
CD45

Cell Population Positive for Marker
Stem cells
Stem and progenitor cells
Early macrophages
Granulocytes
Macrophages
B-cells
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Figure 4.5: No significant differences in myeloid progenitor cell maturation rate
between n-3 and n-6 FAs. EML cells were cultured in either vehicle control, arachidonic
acid (n-6), or eicosapentanoic acid (n-3) for 24 hours then induced to differentiate for
another 72 hours down myeloid lineages. A. Flow cytometry was performed analyzing
the larger FSC population of cells. B. The percentage of cells displaying various markers
of differentiation is shown for each culture type. C. Representative histograms are
displayed for the isotype control (black, narrow line), vehicle control (dotted line), EPA
treated cultures (gray line), and ARA treated cultures (black, thick line). Both FA treated
cultures display a small shift over to the right indicating a small increase in fluorescence
of the F4/80 antigen, but the ARA treated cultures show a greater shift (more cells
present in the higher fluorescence channels). Data represent the results from five
independent experiments with the mean and SEM displayed. (*) indicates statistically
significant (p-value < 0.05) difference based on one-way Kruskal-Wallis analysis of
variance on ranks followed by Dunnett test. (**) indicates statistically significant (pvalue < 0.05) difference based on Student’s t-test without multiple comparison
adjustment.

Discussion
Our primary objective of this study was to determine if the reduction of later
myeloid progenitor subtypes by diets high in n-3 FAs seen previously [12] was the
continuation of differences induced at earlier stages of myeloid progenitor development.
The data from these experiments indicate that this is not the case. The effect of lowering
the frequency of myeloid progenitors of the later stages in mice fed n-3 FA rich diet was
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recapitulated in the present study, but we did not see a lowering of the stem/early
progenitor cell fractions in the bone marrow. Conversely, we observed an increase in the
common myeloid progenitor cell fraction with flow cytometry. Thus, the effects of n-3
FAs on stem/progenitor cell biology in bone marrow are not a simple lowering of the
overall frequency of these cell types. Determination of the exact mechanism of n-3 FA
effects will entail studies at multiple levels of maturation in bone marrow. Possible
mechanisms include effects through metabolites such as leukotrienes, resolvins,
incorporation into cell signaling molecules such as hedgehog, or production of
prostaglandins. Our data suggest that these mechanisms are eventually triggering a
slowed differentiation between the early and middle myeloid progenitor phases resulting
in an increase in early progenitors and a decrease in later stage progenitors in high n-3
diets. Understanding the mechanisms involved will enable targeted therapies for
hematopoietic disorders involving problematic differentiation.
Our in vivo studies indicate that diets rich in n-3 FAs when compared to n-6 FAs
have an effect of increasing the frequency of CMPs but no effect on HSCs (Fig 4.2). The
changes seen in early stem/progenitor cell biology are then reversed, in that diets rich in
n-6 FAs produce an increased number of later stage progenitor cells of the granulocyte
and macrophage lineage (Fig 4.1). The results of our stem cell culture model found no
lasting effects on stem cell viability or proliferation when cultured in n-3 vs. n-6 FAs
(Fig. 4.4A), similar to that seen in vivo. It is interesting that we didn’t see an increase in
HSCs with the corn oil diet containing high n-6 FA levels considering the recent results
indicating one of the products of n-6 FAs, prostaglandin E2, can increase HSC
production in vivo [19-22]. This may be due to the complex metabolism of FAs and the
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use of them in biomolecules or to the genetics of the C57BL/6 model. We found a low
level expression of F4/80 antigen upon treatment with ARA, characteristic of
macrophage progenitor development [23-26], consistent with these progenitors being
greater in vivo in corn oil fed mice compared to fish oil fed mice (Fig. 4.1). No other
significant changes were seen in differentiation state upon treatment with ARA or EPA in
comparison to vehicle controls. We observed a lower proliferation rate during
differentiation of EML cells while cultured in EPA compared to vehicle controls that
wasn’t seen with ARA treatment. This finding is consistent with an overall lowering of
middle-later stage myeloid progenitor cell numbers in mice fed fish oil diets relative to
corn oil diets (Fig.4.1). An important consideration in extrapolating these in vitro
experiments to our in vivo results is that the EML cell model only takes into account cell
autonomous factors. The stem cell niche is an important part of stem cell biology and it is
not recapitulated in this model.
These data indicate that the effect of n-3 FAs in the diet of mice on reducing later
stage myeloid progenitors is not a simple reduction of HSCs in the bone marrow relative
to n-6 FA fed mice. n-3 FAs appear to have a diverse effect depending upon the stage of
progenitor cell development. Understanding the mechanisms involved will allow a more
targeted approach to using n-3 FAs clinically in differentiation therapies. We are
currently investigating whether the use of n-3 FAs as a mechanism of induced
differentiation is applicable to reduction of the progression of chronic myelogenous
leukemia (CML) to the lethal blast crisis phase in a murine model as well as clinical trials
with B-cell malignancies ([27] and unpublished results).

115

Authors' contributions
MEV was responsible for the in vivo data acquisition. MEV and VES analyzed
data and wrote this manuscript. WEH provided intellectual contributions on study design,
and the mice with appropriate diets. VES and MEV provided intellectual contribution on
study design as well. VES coordinated the project. YD offered statistical expertise.

Acknowledgments
This work was supported by NIH grants 1R03 CA129790 to VES, 1R01
CA114018 to WEH, COBRE (5P20RR020180) to Richard M. Niles, and the WV-INBRE
Program (5P20RR016477) to Gary O. Rankin, as well as with support from the NASA
WV Space Grant Consortium issued by NASA Goddard Space Flight Center, Grant
Number NNG05GF80H. We would like to acknowledge John Wilkinson IV for
assistance in discussion of results.

116

References
1. Kelley, D.S., Modulation of human immune and inflammatory responses by dietary
fatty acids. Nutrition, 2001. 17(7-8):669-73.
2. Dupuis, F., et al., Effects of lipidic mediators on the growth of human myeloid
anderythroid marrow progenitors. J Lipid Mediat Cell Signal, 1997. 16(3):117-25.
3. Germain, E., et al., Dietary n-3 polyunsaturated fatty acids and oxidants increase rat
mammary tumor sensitivity to epirubicin without change in cardiac toxicity. Lipids, 1999.
34 Suppl:S203.
4. Hardman, W.E., et al., Effects of iron supplementation and ET-18-OCH3 on MDAMB 231 breast carcinomas in nude mice consuming a fish oil diet. Br J Cancer, 1997.
76(3):347-54.
5. Karmali, R.A., Historical perspective and potential use of n-3 fatty acids in therapy of
cancer cachexia. Nutrition, 1996. 12(1 Suppl):S2-4.
6. Oberley, L.W. and D.R. Spitz, Assay of superoxide dismutase activity in tumor tissue.
Methods Enzymol, 1984. 105:457-64.
7. Li, D., et al., Contribution of meat fat to dietary arachidonic acid. Lipids, 1998.
33(4):437-40.
8. Hagve, T.A. and B.O. Christophersen, Effect of dietary fats on arachidonic acid and
eicosapentaenoic acid biosynthesis and conversion to C22 fatty acids in isolated rat liver
cells. Biochim Biophys Acta, 1984. 796(2):205-17.
9. Rose, D.P. and J.M. Connolly, Omega-3 fatty acids as cancer chemopreventive agents.
Pharmacol Ther, 1999. 83(3):217-44.
10. Rizzo, M.T., The role of arachidonic acid in normal and malignant hematopoiesis.
Prostaglandins Leukot Essent Fatty Acids, 2002. 66(1):57-69.
11. Report of the American Institute of Nutrition ad hoc committee on standards for
nutritional studies. J Nutr, 1977. 107(7):1340-1348.
12. Sollars, V.E., et al., Analysis of expansion of myeloid progenitors in mice to identify
leukemic susceptibility genes. Mamm Genome, 2006. 17(8):808-21.
13. Miller, C.L., B. Lai, Human and Mouse Hematopoietic Colony-Forming Cell Assays.
In Basic Cell Culture Protocols, Volume 290. 3rd edition. Edited by: Helgason CD,
Miller CL. Totowa, NJ: Humana Press Inc; 2005:71-90.
14. Tsai, S., et al., Lymphohematopoietic progenitors immortalized by a retroviral vector
harboring a dominant-negative retinoic acid receptor can recapitulate lymphoid, myeloid,
and erythroid development. Genes Dev, 1994. 8(23):2831-41.
117

15. Hardman, W.E. and G. Ion, Suppression of implanted MDA-MB 231 human breast
cancer growth in nude mice by dietary walnut. Nutr Cancer, 2008. 60(5):666-74.
16. Varney, M.E., W.E. Hardman, and V.E. Sollars, Omega 3 fatty acids reduce myeloid
progenitor cell frequency in the bone marrow of mice and promote progenitor cell
differentiation. Lipids Health Dis, 2009. 8:9.
17. Atkinson, T.G., H.J. Barker, and K.A. Meckling-Gill, Incorporation of long-chain n-3
fatty acids in tissues and enhanced bone marrow cellularity with docosahexaenoic acid
feeding in post-weanling Fischer 344 rats. Lipids, 1997. 32(3):293-302.
18. Akashi, K., et al., A clonogenic common myeloid progenitor that gives rise to all
myeloid lineages. Nature, 2000. 404(6774):193-7.
19. Frisch, B.J., et al., In vivo prostaglandin E2 treatment alters the bone marrow
microenvironment and preferentially expands short-term hematopoietic stem cells. Blood,
2009. 114(19):4054-63.
20. Hoggatt, J., et al., Prostaglandin E2 enhances hematopoietic stem cell homing,
survival, and proliferation. Blood, 2009. 113(22):5444-55.
21. Goessling, W., et al., Genetic interaction of PGE2 and Wnt signaling regulates
developmental specification of stem cells and regeneration. Cell, 2009. 136(6):1136-47.
22. Lord, A.M., T.E. North, and L.I. Zon, Prostaglandin E2: making more of your
marrow. Cell Cycle, 2007. 6(24):3054-7.
23. Gordon, S., et al., Localization and function of tissue macrophages. Ciba Found
Symp, 1986. 118:54-67.
24. McKnight, A.J., et al., Molecular cloning of F4/80, a murine macrophage-restricted
cell surface glycoprotein with homology to the G-protein-linked transmembrane 7
hormone receptor family. J Biol Chem, 1996. 271(1):486-9.
25. Torroella-Kouri, M., et al., Identification of a subpopulation of macrophages in
mammary tumor-bearing mice that are neither M1 nor M2 and are less differentiated.
Cancer Res, 2009. 69(11):4800-9.
26. Zhou, Z., et al., Development and function of myeloid-derived suppressor
cellsgenerated from mouse embryonic and hematopoietic stem cells. Stem Cells, 2010.
28(3):620-32.
27. Witte, T.R., et al., RBC and WBC fatty acid composition following consumption of
an omega 3 supplement: lessons for future clinical trials. Lipids Health Dis, 2010. 9:31.

118

Chapter 5: Discussion
Our research supports our hypotheses that genetic components as well as
environmental components, specifically dietary fatty acids (FAs), regulate progenitor cell
frequency. By understanding how hematopoiesis is influenced, we may better understand
why it goes awry in hematological malignancies. In chapter 2, in silico mapping suggests
that genes involved in the processes of lipid metabolism and bone remodeling play a key
role in regulating myeloid progenitor cell frequency. In chapters 3 and 4, we show that
the ratio of omega-3 (n-3) to omega-6 (n-6) FAs also plays a key role in this process.
Both genetic and environmental components should be considered in attempts to identify
mechanisms by which dysregulated hematopoiesis may lead to myeloproliferative
diseases, myelodysplastic syndromes, and acute myelogenous leukemia (AML).
Identifying potential biomarkers and/or risk factors for AML prognosis is of value
as alterations in the effects of these may give patients increased survival and lessened
recurrence rate. Our data collectively suggest that FA content in the diet, metabolism, and
bone properties are key regulators of hematopoiesis. Our in vivo and in vitro studies
revealed that FA content in the diet has significant influence on myeloid progenitor cell
frequency. Our genetics studies suggest that the way in which FAs are processed by the
body also influences myeloid cell frequency. As insulin affects fat stores, it is not
surprising that patterns of insulin related genes presented in chromosomal regions of high
-logp values in our in silico study as well. Insulin stops the use of fat as an energy source
and has a direct effect on FA synthesis in the body. Therefore, lack of control of insulin
levels can have a profound effect on fat stores in the body [1]. Fat affects bone mineral
density and bone volume [2]. The properties of the bone are part of the microenvironment
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for hematopoiesis. Our research presents genes of interest as potential new biomarkers
and risk factors in the areas of metabolism and bone properties for AML. The support for
association of genes identified in our analysis is strong; however, causation must first be
established in our system.

In silico mapping studies
In silico mapping across 27 strains of inbred mice revealed patterns of genes
located in chromosomal regions of the highest -logp values. Use of this method for
identification of chromosomal loci containing genes of interest in regulating myeloid
progenitor cell frequency was successful, as made evident by the high -logp value
associated with the region of chromosome 14 containing interleukin 3 receptor alpha
(IL3-R. This region served as a control for our study since the region presented in a
previous study, and it is known that the IL3-R gene has a 5bp deletion in some mouse
strains that results in lowered myeloid progenitor cell frequency [3, 4]. Additionally, loci
in mouse chromosome 11 presented in our study are syntenic with the region of human
chromosome 5 that undergoes deletion in a myelodysplastic syndrome called 5qsyndrome [5]. Additional genes contained within regions found in our study overlap with
more traditional quantitative trait loci (QTL) studies for importance in stem and
progenitor populations (Table 5.1) [6,7]. Our studies, however, show greater resolution.
Though our results showed several smaller peaks of significance in chromosome 14,
theses peaks span a large range, which is similar to the results found in previous
traditional QTL studies (Fig. 5.1). A schematic representative of our resulting genes of
interest is show in Figure 5.2.
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Table 5.1: In silico mapping overlaps traditional QTL studies
Previous QTLs
4(37.6-48.5 and 66-78.5cM )
9(23-27cM)

Peaks of Interest in our In Silico Study
4(42.13-45.76cM and 74.75-75.77cM)
9(23.07-24.07cM)

14 (broad range)

14(Several peaks within)

Chromosome 14 9.17-18.48
p-value 0.001-0.005 LOD 7.84
Figure 5.1: Chromosome 14 contains a wide range of high peaks. The 9.17-18.48Mb
region of chromosome 14 has a LOD (logarithm (base 10) of odds) score of 7.84. This
image was created using data from in silico mapping in Chapter 2 (GEMM phenotype).
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Figure 5.2: Schematic summary of resulting genes of interest from in silico mapping.
Representative examples of mouse chromosomes 1-19 are shown. Regions of interest
along chromosomes are indicated with red lines and blue bars. The GEMM phenotype
has associations of interest with regions on chromosomes 5, 6, 7, 8, 14, and 18. The GM
phenotype has associations of interest with regions on chromosomes 14 and 15. The E
phenotype has associations of interest with regions on chromosomes 5, 9, and 11. The G
phenotype has associations of interest with regions on chromosomes 8, 11, and 13. The
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M phenotype has associations of interest with regions on chromosomes 2, 3, 11, 14, 15,
18, and 19. The total phenotype has associations of interest with regions on chromosomes
11 and 14.

In our goals of identifying loci associated with myeloid progenitor cell frequency
as it relates to hematological malignancies, signaling pathway analysis was performed.
Ingenuity Pathway Analysis (IPA) results showed the following pathways to be in the
most significant for the top 50 genes found within chromosomal loci of the highest -logp
values: gene expression, cancer, hematological disease, tumor morphology, genetic
disorder, cell morphology, cell development, and cell cycle. As these are all important
factors for leukemia, this further supports our method. In our literature searches, 30% of
these top genes of interest were involved in cancer. Fifteen percent were associated
specifically with leukemia. Eleven percent of genes were associated with hematopoiesis.
Signaling networks from IPA also included many metabolic networks as well as
reproductive system disease, and others. In completing literature searches on these genes
as well, we found that 20% of genes had known association with dietary fat, FA uptake
and oxidation, lipid metabolism, and atherosclerosis susceptibility. Atherosclerosis is a
condition in which artery walls thicken as the result of a build-up of fatty materials.
Nineteen percent of the top genes had association with insulin or diabetes. Eighteen
percent had associations with bone properties. Many calcium and estradiol signaling
genes presented in these top genes lists as well. This may be why the reproductive system
disease presented as a top signaling pathway in IPA, as-estradiol is in the center of this
network and is known to be vitally important in bone properties [8].
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Additional nodes or connection points in pathways of significance in IPA were
transforming growth factor beta 1 (Tgf1) and hepatocyte nuclear factor 4 alpha (Hnf4).
Tgf1 is known to be important to the process of hematopoiesis as it is a critical regulator
for in vivo homeostasis of hematopoietic stem cells (HSCs), especially for their homing
potential [9]. Furthermore, it has significant effects on bone. It functions to couple bone
resorption and formation. Tgf1 released during bone resorption coordinates bone
formation by inducing migration of bone marrow stromal cells to bone resorptive sites
[10]. It also works to suppress osteoclast apoptosis [11]. Hnf4 is involved in
coordinating the expression of genes involved in FA transport and metabolism [12].
Hnf4 regulated genes are also correlated with femur strength [13]. It has also been
shown to serve as a molecular switch in transdifferentiation of hematopoietic cells to
hepatocytes in vitro by decreasing myeloid colony-forming potential and increasing
expression of hepatocyte-specific genes and proteins [14].
Given these results and understanding of the relationships between insulin,
metabolism, and bone properties, it will be interesting to determine if these processes,
and the particular genes that presented in the chromosomal loci with the highest -logp
values, in fact regulate hematopoiesis, with particular polymorphisms conferring
susceptibility to hematological malignancies. Many insulin and diabetes associated genes
in our study have been shown to have a major role in metabolism and bone remodeling
[15-22]. As dietary fat content has been shown to regulate bone mineral density and bone
volume, and as several QTLs for body size (body weight, length, and adipose mass)
correlate with those identified for skeletal traits, there is evidence to suggest that many
QTLs may regulate bone properties via their effect on body size [2,23]. Because the
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microenvironment, including osteoclasts and osteoblasts, is highly involved in regulating
hematopoiesis, it makes sense that the following process may be in effect (Fig. 5.3) [24].
Fat in the diet and how the body metabolizes and/or stores it along with the role of insulin
in regulating fat stores and FA synthesis in the body, determine bone mineral density,
which is the result of the work of competing osteoblasts and osteoclasts, each of which
have effects on hematopoiesis [25-28]. Additionally, osteoclasts regulate insulin
signaling in osteoblasts, which control whole body glucose homeostasis [29].
Furthermore, within the hematopoietic niche, marrow fat and bone mineral density are
inversely related. Accelerated marrow adipogenesis has been associated with aging and,
interestingly, diabetes mellitus and osteoporosis [30]. To address the importance of this
component of the niche, Figure 5.4 shows the prevalence of adipocytes in a normal
section of long bone.
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Dietary FA Content Controls Insulin Sensitivity

Insulin Promotes FA Synthesis and Inhibits
the Breakdown of Fat

Diet, Lipid Metabolism, and Fat Control
Bone Mineral Density

Lymphoid Progenitor Cells

Hematopoietic
Stem Cell

Myeloid Progenitor Cells

Insulin
Bone
Matrix

Blood
Vessel

Osteoclasts
Control Insulin
Signaling
In Osteoblasts

Stromal
Cell

Insulin
Receptor

Whole Body
Glucose
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Osteoblast
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Figure 5.3: Schematic for relationships of dietary fatty acids, insulin, metabolism,
bone properties, and hematopoiesis. Omega FA content in the diet is involved in
controlling glucose levels and regulating insulin sensitivity. Insulin stops use of fat as an
energy source and promotes synthesis of FAs. Fat from the diet and lipid metabolism
regulate bone mineral density among other bone properties. Osteoblast and osteoclast
work against one another in controlling mineralization of the bone. Osteoclasts regulate
insulin signaling in osteoblasts, which regulate whole body glucose homeostasis. The
microenvironment regulates hematopoiesis.
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*

Figure 5.4: Hematopoietic niche histology. This section of long bone illustrates the
prevalence of adipocytes (large circular cells, example shown with asterisk) within the
hematopoietic niche. This photo was taken using a Nikon Eclipse 80i microscope fitted
with the SPOT Pursuit CCD camera (Diagnostic Instruments, Inc., Sterling Heights, MI)
at 20X magnification.

Dietary fatty acid studies
Corroborating the results of our in silico mapping studies, our studies of the effect
of the diet on hematopoiesis revealed that dietary FA content significantly affects
myeloid progenitor cell frequency. In our study of FVB X sv129 F1hybrid mice, we
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found that a diet with higher n-3 FA content reduces total myeloid progenitor cell
frequency and promotes differentiation of specific progenitor cell types in the bone
marrow without having an adverse effect on levels of circulating white blood cells. Our
data indicate that n-3 FA effects are particular to granulocyte and macrophage progenitor
cells rather than erythrocyte maturation. Our results indicated a difference at the
granulocyte macrophage (GM) progenitor stage and were suggestive, but inconclusive, of
a difference at the granulocyte erythrocyte macrophage megakaryocyte (GEMM) stage.
Our results presented the following question: is the reduction in middle and late stage
progenitors by diets rich in n-3 FAs a continuation of differences induced at earlier stages
of myeloid progenitor development?
Our second FA study addressed this question by investigating effects of dietary
FAs at the earliest stem and progenitor cell stages of hematopoiesis. We examined the
effects of n-3 and n-6 FAs in vivo in C57BL/6 mice, with an analysis at the level of stem
and progenitor subtypes. Our results were consistent with the previous study in that
compared to diets rich in n-6 FAs, diets rich in n-3 FAs induce lower levels of later stage
myeloid progenitor cells in mice. We found, however, that reduction in late stage
progenitor cells was not a continuation of any reduction in earlier progenitors or stem
cells. Using flow cytometry, we found the common myeloid progenitor fraction was
instead increased in these mice, suggesting that there are differentiation mechanisms
responsible for an increase in early progenitors and a decrease in later stage progenitors
in high n-3 diets. There was no difference in HSCs.
We performed in vitro studies as well to examine if the in vivo effects of n-3 and
n-6 FAs could be modeled using the EML cell culture system to more readily ascertain
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mechanisms involved. We found no lasting effects on stem cell viability or proliferation
when cultured in n-3 vs. n-6 FAs, similar to that seen in vivo. We did find a low level
expression of F4/80 antigen upon treatment with arachidonic acid (ARA) treatment,
characteristic of macrophage progenitor development, and consistent with these
progenitors being greater in vivo in corn oil fed mice compared to fish oil fed mice. No
other significant changes were seen in differentiation state upon treatment with ARA or
eicosapentanoic acid (EPA) in comparison to vehicle controls. Consistent with an overall
lowering of middle-later stage myeloid progenitor cell numbers in mice fed fish oil diets
relative to corn oil diets, in our in vitro model, we observed a lower proliferation rate
during differentiation of cells cultured in EPA compared to vehicle controls that wasn’t
seen with ARA treatment. Our conclusion was that the EML cell culture model was able
to accurately model some aspects of FA effects on early hematopoietic stem and
progenitor biology.
It is important, however, to realize that the EML cell model only takes into
account cell autonomous factors. The hematopoietic microenvironment is an important
part of stem cell and progenitor cell biology and this is not recapitulated in this model. As
noted previously, dietary fat content has significant effects on bone mineral density, and
osteoclasts and osteoblasts have been shown to affect hematopoiesis. A model without
these factors present can give us only a limited idea of what is taking place at the whole
organism level. Further research into the mechanisms controlling this complex regulation
of stem and progenitor cell frequency by FAs may provide key information to target
therapies to hematopoietic disorders.
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In silico mapping and dietary fatty acid studies
We have found that there are chromosomal loci associated with myeloid
progenitor frequency and that these loci present interesting patterns when examining the
genes within them. We have found that dietary n-3 to n-6 FA ratios play a significant role
in controlling progenitor cell frequency. After discovering these answers to the questions
originally proposed, new questions are presented. What possible mechanisms exist that
combine dietary FA content with patterns of metabolic pathways and bone properties for
controlling myeloid frequency?
In attempting to answer this question, I am proposing new hypotheses. As n-3
FAs have been associated with protective functions for osteoblastogenesis and they
decrease osteoclastogenesis and osteoclast differentiation, I hypothesize that osteoblasts,
protected by dietary n-3 FAs, subsequently upregulate granulocyte macrophage colony
stimulating factor (GM-CSF), granulocyte colony stimulating factor (G-CSF), and
interleukin 6 (IL-6), which are responsible for the differentiation of hematopoietic cells
toward the monocyte and granulocyte lineages [26, 31-32]. If this is true, as these
cytokines work to differentiate these cells, there would be fewer cells in progenitor stages
than those in n-6 FA rich diets. Because these cytokines promote granulocyte and
monocyte differentiation, there would be no decrease in erythrocyte progenitors than
when compared to n-6 FA rich diets, which would corroborate the results in our dietary
FA studies (Fig.5.5). In order to address the result of increased common myeloid
progenitors (CMPs) in mice fed n-3 FA rich diets, I additionally hypothesize that the
push of HSCs toward the myeloid lineage by the presence of these cytokines creates an
initial increase in CMPs when compared to a diet rich in n-6 FAs in which HSCs are
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producing an even mix of common lymphocyte progenitors and CMPs. Additionally, the
n-6 FA metabolite prostaglandin E2 (PGE2) significantly lowers macrophage colony
stimulating factor (M-CSF) secretion by bone marrow stromal cells, further supporting
this idea [33].
HSC

MPP
GM-CSF
IL-6
G-CSF
n-3 FA Rich Diet
CMP
Protected
Osteoblastogenesis

Decreased
Osteoclastogenesis

Granulocyte and
Monocyte Lineages

Figure 5.5: Influence of n-3 FA rich diet on myeloid progenitor cell frequency. n-3
FAs protect osteoblastogenesis and prevent osteoclastogenesis. Cytokines released by the
osteoblasts stimulate multi-potential progenitors (MPPs) to differentiate to the myeloid
lineage and continue to differentiate these cells into granulocytes and monocytes.

This finding also presents the idea that if cytokines that support differentiation of
these progenitors are being suppressed in n-6 rich FA diets, these progenitor cells are
given more time in this stage to acquire mutations. Current theory for the acquiring of
leukemia suggests that failure of progenitors to differentiate causes prolonged
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proliferation, thereby increasing the chances that these cells will accumulate events
contributing to cancer progression [34]. On a side note, IL-6, is additionally produced in
the working muscle during physical activity and has been proposed to act as an energy
sensor by enhancing glucose disposal, lipolysis, and fat oxidation [35]. Perhaps this
accounts for an additional role of physical activity in regulating hematopoiesis.
Determination of the exact mechanism of n-3 and n-6 FA effects will entail
studies at multiple levels of maturation in bone marrow. Mechanisms by which n-3 FAs
have been shown to inhibit proliferation, induce apoptosis, and promote differentiation in
many cancers include the regulation of signaling pathways and gene expression by
peroxisome proliferator receptor activator γ (PPARγ), for which n-3 FAs are natural
ligands [36]. Ligand activation of the PPAR-RXR heterodimer complex enhances
insulin sensitivity. Insulin levels affect fat stores, which in turn affect bone composition.
PPAR has also been shown to control bone formation and bone mass through the
modulation of bone marrow stromal cell differentiation [37]. Another mechanism of
action of n-3 FAs includes inhibition of cyclooxygenase 2 (COX2), which is upregulated
in various cancers and is known to have proproliferative and antiapoptotic effects [3846]. COX2 was shown to significantly increase the rate of osteoclast formation in breast
cancer studies [47]. Additional possible mechanisms include effects through metabolites
such as leukotrienes, resolvins, incorporation into cell signaling molecules such as
hedgehog, or production of prostaglandins.
Overall, our studies show that dietary FAs affect myeloid progenitor cell
frequency. They suggest that metabolism and bone properties regulate myeloid
progenitor cell frequency as well. As dietary intake and insulin regulate fat stores in the
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body, fat regulates bone mineral density, and bone microenvironment influences
hematopoiesis, these processes and the genes that control them should be further
investigated in regulating myeloid progenitor cell frequency as it is pertinent to
hematological diseases. As diet is controllable and bone mineral density is fairly easy and
inexpensive to assess, these have great potential to serve as new therapies and risk
prognosis indicators in AML.
Future directions for our lab will include determining if genes located in
chromosomal regions with high -logp values are in fact associated with changes in
myeloid progenitor cell frequency. Our lab will identify these genes through deep
sequencing and determine if evidence supports a causal relationship to myeloid
progenitor frequency in congenic strains. Our lab will also determine if the particular
pathways that emerged the most (bone properties and metabolic processes) are
biomarkers for AML progression risk by assaying mice for parameters associated with
these pathways and determining correlation with myeloid progenitor cell frequency.
Additionally, the validation of the role of these genes and pathways in human
hematopoiesis and AML progression will take place. Bone marrow from AML patients
and normal individuals will be analyzed to determine if the genes and pathways identified
in mice translate to humans. Experiments involving the novel hypotheses presented in
regard to the overall relationships of the FA content in the diet, its effects on bone, and
therefore cytokines secreted in the hematopoietic microenvironment may also be pursued.
Upon subjection to corn or fish oil diet, mice will be assessed for parameters of bone
composition, cytokines in the hematopoietic microenvironment, and hematopoietic stem
and progenitor cell frequencies, including common lymphoid progenitors. Once
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correlation has been established, further investigation into mechanisms of action such as
PPAR activation or COX2 inhibition will pursued.
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